Method of anchoring fragmented nucleic acid targets in polymer matrices for imaging

By using two anchoring agents to form covalent bonds with target nucleic acids and clearing non-target cell components in FFPE tissue sections, the imaging quality problem in in situ single-cell transcriptomics analysis of FFPE tissue sections was solved, achieving efficient target nucleic acid fixation and imaging.

CN119013416APending Publication Date: 2024-11-22VIZGEN INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380033673.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-12
Filing Date
2023-02-17
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing in situ single-cell transcriptomics analysis methods are difficult to apply effectively to formalin-fixed paraffin-embedded (FFPE) tissue sections, mainly due to background noise caused by RNA degradation and protein cross-linking, which affects imaging quality.

Method used

Two anchoring agents were used to form covalent bonds with the target nucleic acid and embed it in a polymer matrix. Then, non-target cell components were cleaned up, the target nucleic acid was immobilized, and imaging was performed using primary and secondary nucleic acid probes.

Benefits of technology

It significantly improved the imaging quality and data accuracy of FFPE tissue sections, enabled efficient in situ single-cell transcriptomics analysis, and enhanced the fixation and imaging efficiency of target nucleic acids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013416A_ABST
    Figure CN119013416A_ABST
Patent Text Reader

Abstract

The present disclosure generally relates to methods for anchoring nucleic acids in a matrix and subsequently imaging nucleic acid targets (e.g., RNA transcript molecules) within a tissue sample, such as a formalin-fixed paraffin embedded (FFPE) tissue section, wherein the nucleic acids may be fragmented. For example, provided herein is a method of anchoring a target nucleic acid within a matrix and cleaning non-target cellular components and comprising contacting a tissue sample with at least two anchoring agents wherein the first anchoring agent forms a covalent bond with the target nucleic acid and the second anchoring agent contains an oligonucleotide that hybridizes to the target nucleic acid; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; and cleaning the non-target cellular fraction from the polymer matrix wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix anchored target nucleic acid sample. Additional steps include contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes, the one or more primary oligonucleotide probes hybridizing to the target nucleic acid and a plurality of secondary nucleic acid probes, the secondary nucleic acid probe contains a fluorescent label and a recognition sequence hybridized with the sequence of the primary nucleic acid probe; and imaging the target nucleic acid.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the claims of provisional application No. 63 / 311,319 filed on February 17, 2022; and U.S. Serial No. 63 / 424,891 filed on November 12, 2022, each of which is hereby incorporated into this application in its entirety. Technical Field

[0002] The present application relates generally to the field of in situ imaging, and in particular to methods of determining nucleic acid targets within a tissue sample. Background Art

[0003] To accurately analyze gene expression in tissue samples in situ, spatial transcriptomics techniques with high detection efficiency and single-molecule resolution are required. In situ single-cell transcriptomics imaging techniques such as multiplexed error-robust fluorescence in situ hybridization (MERFISH) can directly analyze the spatial organization of intact tissues at subcellular resolution.

[0004] However, background (from factors such as cell autofluorescence) usually makes in situ imaging applications in tissue samples more challenging. Without wishing to be bound by any theory, it is believed that certain components (such as proteins and lipids, unbound or unrelated nucleic acids, fluorescent components (bleached or unbleached), etc.) may cause problems when imaging or analyzing, for example, due to autofluorescence, components of quenching fluorescent molecules, off-target binding or other phenomena. For example, it is believed that nucleic acid probes may not bind to the appropriate target in the sample, but may "off-target" bind to other cellular components, including but not limited to proteins, lipids, RNA, DNA, etc. Similarly, a probe targeting a DNA or RNA molecule may "off-target" bind to the wrong DNA or RNA molecule. These interactions can be driven, for example, by imperfect base pairing, charge-to-charge interaction or other molecular interactions. Therefore, a polymer matrix or gel can be applied to a sample to fix the desired nucleic acid molecule (or other desired target), and the components ("non-target cell components") of the nucleic acid probe off-target binding can be removed or degraded from the sample. This can reduce the amount of the probe off-target binding, thereby promoting imaging or other analysis of the sample. Other components, such as proteins and lipids, can be removed or degraded from the sample. This can reduce the amount of background, thereby facilitating imaging or other analysis of the sample. The method developed for removing cellular components from gel-embedded tissue sections works well enough for fresh and fixed frozen samples, where the anchor oligonucleotides and target probes are added to the sample, then embedded in a gel, and the cellular components are cleaned up or removed before imaging ("Scheme B"). See Figure 1 When used with formalin-fixed paraffin-embedded ("FFPE") tissue sections, the methods as provided herein are insufficient for fixation of target nucleic acids and insufficient for hybridization of target probes to nucleic acids for imaging.

[0005] For example, methods for preparing samples for MERFISH imaging are disclosed in U.S. Patent Publication 2019 / 0264270 entitled "Matrix Imprinting and Clearing" (the contents of which are incorporated herein by reference). However, MERFISH imaging has been previously demonstrated in fresh and fixed frozen tissue blocks, but not previously in formalin-fixed paraffin-embedded (FFPE) tissue sections. In fact, although FFPE tissue sections are the most widely used clinical sample type in histology and molecular diagnosis, it is known that FFPE samples are often incompatible with in situ single-cell transcriptomic analysis due to RNA degradation and protein cross-linking. Therefore, methods and / or reagents that allow in situ single-cell transcriptomic analysis of FFPE tissue samples are needed.

[0006] Thus, the present disclosure provides improved methods for imaging nucleic acid targets, including preparation of tissue samples that allow for in situ single cell transcriptomic imaging (eg, MERFISH) of FFPE tissue sections. Summary of the invention

[0007] Methods and reagents for in situ single-cell transcriptomic analysis of FFPE tissue sections or other tissue samples suspected of nucleic acid fragmentation are described herein. In an embodiment, a method for anchoring and imaging a target nucleic acid molecule (e.g., mRNA transcript) from a FFPE tissue sample is provided herein, the method comprising: a) contacting the tissue sample with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises an oligonucleotide hybridized with the target nucleic acid; b) embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer gel; c) cleaning the non-target cell components from the polymer matrix, wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix-anchored target nucleic acid sample. In certain embodiments, the method further comprises an imaging step d) contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes, the one or more primary oligonucleotide probes hybridizing with the target nucleic acid and a plurality of secondary nucleic acid probes, the secondary nucleic acid probes comprising a fluorescent label and a recognition sequence hybridized with the sequence of the primary nucleic acid probe; and imaging the target nucleic acid. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 A comparison of Scheme A (the method of the present disclosure) and Scheme B (the comparative scheme) is shown. See Example 1.

[0009] Figure 2A-2CShown is MERFISH imaging using a 128-plex gene detection panel in FFPE mouse small intestine tissue sections according to Example 1 (Protocol A). Figure 2A The spatial distribution of selected genes in tissues is shown; Figure 2B Tissue morphology visualized by selected transcripts (left) and the distribution of all transcripts in the magnified area are shown; Figure 2C Correlation of MERFISH counts with bulk RNA sequencing FPKM (fragments per kilobase of transcript per million mapped reads) data is shown, indicating that the measurements are quantitative and highly accurate. Scale bar: 1 mm. See Example 2.

[0010] Figure 3A-3C Shown is MERFISH imaging using a 244-plex gene detection panel in FFPE human colon cancer tissue sections according to Example 1 (Protocol A). Figure 3A ) The spatial distribution of selected genes in tissues; Figure 3B ) Tissue morphology visualized by selected transcripts (left) and the distribution of all transcripts in the magnified area; Figure 3C ) Correlation of MERFISH counts with bulk RNA sequencing FPKM data. Scale bar: 1 mm. See Example 2.

[0011] Figure 4A-4C Shown is MERFISH imaging using a 483-plex gene detection panel in FFPE mouse brain tissue sections according to Example 1 (Protocol A). Figure 4A ) The spatial distribution of selected genes in tissues; Figure 4B ) Tissue morphology visualized by selected transcripts (left) and the distribution of all transcripts in the magnified area; Figure 4C ) Correlation of MERFISH counts with bulk RNA sequencing data. Scale bar: 1 mm. See Example 2.

[0012] Figure 5 A comparison of sample preparation according to the protocol of Example 1 ("Protocol A") and a comparative protocol ("Protocol B") is shown. For Protocol B, MERFISH probes (e.g., primary oligonucleotide probes) and anchor probes were added prior to the tissue clearing step. FFPE mouse small intestine samples were processed with Protocol A or Protocol B, and fresh frozen mouse small intestine samples were processed with Protocol B. The average transcript counts per field of view (FOV) under both conditions are shown. N=3. See Examples 3 and Figure 1 .

[0013] Figure 6A-6CMERFISH imaging using a 244-plex gene panel in 15 different archived human FFPE tissue section samples is shown. For each dataset, 1000-2000 fields of view were captured, generating tens to hundreds of millions (10s-100s million) of counts per tissue slice. Fig. 6A ) Average MERFISH counts per field of view (area size 200X200μm), demonstrating that the workflow works robustly across a wide range of human normal and cancer FFPE tissue section samples. Figure 6B )MERFISH data quality correlates with the RNA quality of the sample, as shown by DV200 values ​​above 40%. DV200 is the percentage of RNA fragments >200 nucleotides in a sample. Figure 6C ) Correlation of MERFISH counts with bulk RNA sequencing FPKM data in different tissues. See Example 4.

[0014] Figure 7 A comparison of samples prepared according to the protocol of Example 1 ("Protocol A") and a comparative method ("Protocol B") in different sample types is shown, showing the average counts per field of view (area size 200X 200μm) and the correlation of MERFISH data in different tissue types, including the correlation coefficient for each tissue type. See Example 5.

[0015] Figure 8 It was shown that Protocol A outperformed Protocol B in various fresh frozen (FF) human samples while maintaining the accuracy of the measurement results. Figure 8 A) Using a panel of 244 genes, fresh frozen human lymph node, lung, colon and kidney samples were treated with either protocol A (target nucleic acid anchored first and hybridized after polymer matrix embedding and cleanup of non-target cellular components) or protocol B. B, All samples were then imaged on MERSCOPE. The average transcript counts per field of view (FOV) for both conditions are shown.

[0016] Fig. 9 It was shown that Protocol A outperformed Protocol B in various fresh frozen (FF) human samples while maintaining the accuracy of the measurements, where in human lung and kidney samples, the imaged transcripts for each gene using Protocol A correlated with the imaged transcripts for each gene using Protocol B. The correlation coefficients were 0.99 and 0.98, respectively, indicating that Protocol A was able to recapitulate the expression levels measured by Protocol B, and that there were significantly more counts using Protocol A overall.

[0017] Figure 10A-10C The FFPE workflow was shown to be highly sensitive, accurate, and reproducible. Fig. 10AThe correlation of MERSCOPE data between two human ovarian cancer slices from the same patient is shown. The correlation coefficient is 0.99, indicating that the measurements are highly reproducible. Fig. 10B In Figure 1, human ovarian cancer sample 1 was analyzed by MERSCOPE using a 500-gene panel and adjacent slices were analyzed by bulk RNA sequencing. A correlation analysis between MERFISH counts and FPKM values ​​from bulk RNA sequencing is shown. The correlation coefficient is 0.82, indicating that the measurements are highly accurate. Fig. 10C Correlation analysis between MERSCOPE data and bulk RNA sequencing performed in 14 cancer samples is presented, and the correlation coefficients indicate high accuracy across multiple cancer types and replicate experiments. See Example 8.

[0018] Figures 11A-11F We show that the FFPE cell segmentation workflow enables the creation of realistic atlases in dense tissues. Fig.11A FFPE human hepatocellular carcinoma was immunostained using the Cell Border Staining Kit and DAPI for nuclei staining. Fig. 11B In Figure 1, cells are segmented using a deep learning-based cell segmentation algorithm. A polygonal mask for each identified cell is shown. Fig. 11C Shown is a UMAP visualization of 17 different cell types identified in human liver cancer generated from MERFISH transcript data. Fig.11D Shown in the Fig. 11B Spatial distribution of the cell types identified in the boxed areas in the tissue. Fig.11E Shown in the Fig. 11B Spatial distribution of fibroblasts in the boxed area. Fibroblast marker gene COL1A1 (shown in yellow). Fig.11F Shown is a partial distribution of endothelial cells in the boxed area from B. The endothelial marker gene PECAM1 is shown in green. See Example 8.

[0019] Fig.12 The spatial distribution of cell types identified in different FFPE tumor samples is shown. Different cancer samples, including breast cancer, colon cancer, melanoma, lung cancer, liver cancer, ovarian cancer, prostate cancer and uterine cancer, were analyzed by using MERSCOPE with a 500-gene detection panel and a cell border staining kit for marking cell borders. The cells were segmented and subjected to single cell analysis. The cells identified in each sample were colored to show the spatial distribution of different cells in the sample. Scale bar: 1 mm. See Example 8.

[0020] Figure 13 shows that the FFPE protocol can be used to demonstrate the spatial distribution of expression of selected genes (ACTA2, CD3D, LGR5, MK167 and PECAM1) in human breast cancer. Fig.13A The spatial distribution of selected genes in tissues including ACTA2 (green), CD3D (red), LGR5 (aqua), MKI67 (magenta) and PECAM1 (blue) from the 500 genes analyzed is shown. Scale bar: 1 mm. Fig. 13B Provided Fig.13A Magnified view of the boxed area. Scale bar: 1 mm. Fig. 13C Shows Fig. 13B Magnified view of the boxed area, with the cell boundary polygon mask shown in grey. Scale bar: 250 μm. See Example 8.

[0021] Figure 14A-14E It was shown that FFPE protocols can be used for cell type identification and mapping in human breast cancer. Fig.14A Provided are UMAP visualizations of different cell types identified in human breast cancer generated from MERFISH transcript data. Fig. 14B The spatial distribution of the 14 identified cell types in the tissue is shown. Fig. 14C Shown in Fig. 14B Spatial distribution of cell types identified in the boxed area. Fig.14D Shown in Fig. 14C The spatial distribution of two types of fibroblasts (fibroblast 1 shown in green and fibroblast 2 shown in red) in the boxed area of ​​. Both types of fibroblasts express the COL1A1 gene, while fibroblast 2 expresses the proliferation marker MKI67. Fig.14E A dot plot is provided showing marker genes for each cell type. See Example 8.

[0022] Figure 15 shows that FFPE protocols can be used to characterize immune cell types in the tumor microenvironment. Fig.15A A T / NK cell cluster from a breast cancer sample was selected for subcluster analysis. UMAP visualization of subcluster analysis shows seven different immune cell subtypes within human breast cancer. Fig. 15B Dot plots are provided showing marker genes for each immune cell type including myeloid cells, CD4+ T cells, CD8+ T cells, CD4+ regulatory T cells (Tregs), and NK lineage cells. Fig. 15C The spatial distribution of Tregs is provided. Fig.15D The spatial distribution of CD4+ T cells is provided. Fig.15EThe spatial distribution of selected genes within the amplified region in human breast cancer is provided, where CD4, CD8A, FOXP3, NCR1 and CTLA4 are shown. Note that FOXP3 positive Tregs express T cell exhaustion markers. See Example 8. DETAILED DESCRIPTION

[0023] The present disclosure generally relates to preparing tissue samples for in situ imaging when nucleic acid, especially mRNA fragmentation is suspected. In embodiments, the sample is a FFPE tissue sample. The present disclosure also provides the preparation of tissue samples, which allows in situ single cell transcriptomic imaging (e.g., MERFISH, smFISH) to detect nucleic acid targets in the sample. The method of the present disclosure can be used to make the gene expression profile of the tissue sample. Other aspects generally relate to systems or test kits related to such methods, etc.

[0024] In certain embodiments, provided herein are methods and compositions for preparing FFPE samples to be used for transcriptome analysis. In embodiments, transcriptome analysis includes single molecule (sm) FISH, barcoding (also referred to herein as "codeword") methods for quantitative transcriptome-wide transcriptomes, combined barcoding methods for quantitative and spatial transcriptome analysis (e.g., seqFISH), or error correction methods, including hybridization chain reaction (HCR) seqFISH and multiplexed error robustness (MER) FISH.

[0025] In certain embodiments, provided herein are methods for anchoring a target nucleic acid within a matrix and clearing non-target cell components, which can then be used for downstream imaging of a nucleic acid target. In embodiments, the method comprises contacting a tissue sample suspected of containing nucleic acid fragments (e.g., a formalin-fixed paraffin-embedded (FFPE) sample) with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises an oligonucleotide hybridized with the target nucleic acid; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; and, clearing non-target cell components from the polymer matrix, wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix-anchored target nucleic acid sample. In certain embodiments, the target nucleic acid is RNA, particularly mRNA, wherein the method comprises contacting a tissue sample suspected of containing RNA fragments (e.g., a formalin-fixed paraffin-embedded (FFPE) tissue sample) with at least two anchoring agents, wherein the first anchoring agent comprises an alkylating agent that forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises a poly-T sequence that is complementary to and hybridizes to the target RNA, and wherein the first anchoring agent and the second anchoring agent each comprise an acrydite portion that is covalently bound to a matrix; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; and, clearing the non-target cellular components from the polymer matrix, wherein the target RNA remains anchored in the polymer matrix to form a matrix-anchored target RNA sample.

[0026] In certain embodiments, FFPE tissue sections are prepared for transcriptome analysis (e.g., RNA transcripts), including deparaffinization, ethanol rehydration, antigen repair steps, and then at least two anchoring agents (e.g., such as two functionally different or distinct anchoring agents) are added to the tissue sample, wherein the first anchoring agent forms a covalent bond with the target nucleic acid, and the second anchoring agent (also referred to herein as "anchoring probe") comprises an oligonucleotide hybridized with the target nucleic acid. In this way, the target nucleic acid is functionalized with two separate anchoring agents to form an anchored tissue sample. This anchoring treatment step improves the fixation of the target nucleic acid in a gel or polymer matrix, wherein in particular, mRNA can become fragmented during the FFPE process of fixing the tissue section. Each of these anchoring agents further comprises a chemical moiety (e.g., reactive group) that can form a covalent bond with the polymer matrix during or after the polymer matrix is ​​formed (polymerized). Therefore, after at least two anchoring agents are added to the tissue sample, the sample is then embedded in the polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix. In this manner, the target nucleic acid is immobilized in the polymer gel matrix.In certain embodiments, the polymer matrix is ​​a polyacrylamide gel, and the first anchor and the second anchor each comprise a reactive group (eg, acrydite) that forms a covalent bond with acrylamide.

[0027] After the gel embedding step, non-target cellular components are removed using reagents and methods known in the art (e.g., protease digestion) (also referred to herein as a tissue clearing or digestion step). When starting with FFPE tissue samples, this clearing step is combined with the use of at least two anchoring agents to remove protein crosslinks induced by the formalin fixation process, which exposes the target nucleic acid to complementary primary oligonucleotide probes designed to hybridize to the target sequence in the anchored nucleic acid. Comparative Scheme B disclosed herein (see Figure 1 ) includes a step of adding the primary oligonucleotide probe before the cleanup step, which is sufficient for fresh and fixed frozen samples, but significantly reduces the number of imaged transcripts for FFPE samples. See Figure 4. Applicants have found that the combined use of two anchoring agents and the order in which the steps are performed (e.g., adding the primary oligonucleotide probe after anchoring and cleanup) significantly improves the target nucleic acids available for hybridization and visualization.

[0028] Thus, after the final step of tissue cleaning, the initial FFPE tissue sample is prepared and ready for transcriptome analysis according to protocols known to those skilled in the art (e.g., probe hybridization and imaging). In certain embodiments, provided herein are methods for imaging a target nucleic acid within a matrix and cleaning up non-target cell components, the method comprising: contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample or a sample suspected of containing fragmented nucleic acids with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises an oligonucleotide hybridized with the target nucleic acid; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; cleaning up the non-target cell components from the polymer matrix, wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix-anchored target nucleic acid sample; and contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes, wherein the one or more primary oligonucleotide probes hybridize with the target nucleic acid and a plurality of secondary nucleic acid probes, wherein the secondary nucleic acid probe comprises a fluorescent label and a recognition sequence hybridized with the sequence of the primary nucleic acid probe, and imaging the target nucleic acid.

[0029] In certain embodiments, the method includes contacting the nucleic acid target (e.g., RNA transcript) with at least two anchoring agents to enhance the fixation efficiency of the RNA transcript prior to polymer matrix embedding. In embodiments, the method includes tissue cleaning (e.g., removing non-target cell components) prior to contacting the sample with a primary oligonucleotide probe (e.g., MERFISH probe, smFISH probe, etc.) to increase the efficiency of primary probe binding by exposing the target nucleic acid after cross-linking protein cleaning. In certain embodiments, the method comprises contacting an RNA transcript (e.g., a nucleic acid target) with at least two anchoring agents, wherein a first anchoring agent forms a covalent bond with the target nucleic acid and a second anchoring agent (anchoring probe) comprises an oligonucleotide that hybridizes with the target nucleic acid; embedding a tissue sample comprising the at least two anchoring agents in a gel matrix, whereby the RNA transcript is fixed in the polymer gel matrix when the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; digesting or clearing the tissue and / or non-target cellular components, and then contacting the fixed nucleic acid (e.g., RNA transcript) with a plurality of primary oligonucleotide probes that specifically hybridize with the fixed target nucleic acid, and imaging the target nucleic acid.

[0030] In certain embodiments, provided herein is a kit for FFPE sample preparation, the kit comprising one or more of the following reagents: deparaffinization buffer, crosslinking buffer, conditioning buffer, sample preparation wash buffer, formamide wash buffer, gel embedding premix, cleanup premix, gel cover glass, pre-anchoring activator, anchoring buffer and digestion premix. In certain embodiments, the kit of the present disclosure comprises at least two "anchoring buffer" formulations; one comprising a first anchoring agent, and the other comprising a second anchoring agent or anchoring probe.

[0031] Exemplary methods and kits, and components thereof, according to the present disclosure are described in Example 1.

[0032] Thus, in one set of embodiments, a method for detecting (e.g., via imaging) a nucleic acid target in a tissue sample (e.g., FFPE) is provided, the method comprising: contacting a sample containing a nucleic acid target with an anchor probe that specifically binds (e.g., via hybridization) to the nucleic acid target; fixing (e.g., via covalent attachment of the anchor probe to a polymer gel) the nucleic acid target-bound anchor probe in at least a portion of the sample within the gel; clearing the tissue sample within the polymer gel by removing or degrading non-target cellular components (e.g., unfixed target nucleic acids); contacting the sample with a plurality of primary nucleic acid probes that are capable of selectively binding (e.g., hybridizing) to the nucleic acid target; and detecting (e.g., via imaging) the nucleic acid probes bound to the nucleic acid target within the cleared (e.g., gel-embedded) sample.

[0033] In some embodiments, a method for detecting (e.g., via imaging) a nucleic acid target in a tissue sample (e.g., FFPE) is provided, the method comprising: contacting a tissue sample containing a nucleic acid target with an anchoring agent, the anchoring agent comprising a first chemical portion that can react with and / or modify an internal base of the nucleic acid target (e.g., a reactive group that can form a covalent bond with a target nucleic acid) and a second chemical portion that can be incorporated into a polymer gel (e.g., a reactive group that can form a covalent bond with a polymer gel); fixing the anchoring agent bound to the nucleic acid target in at least a portion of the tissue sample within the gel (e.g., via covalent attachment of the anchoring agent to the polymer gel); clearing the tissue sample within the polymer gel by removing or degrading non-targets (e.g., unfixed target nucleic acids); contacting the tissue sample with a plurality of primary nucleic acid probes that can selectively bind (e.g., hybridize) to the nucleic acid target; and detecting (e.g., via imaging) the nucleic acid probes bound to the nucleic acid target within the cleared (e.g., gel-embedded) sample.

[0034] In some embodiments, a method for detecting (e.g., via imaging) a nucleic acid target in a tissue sample (e.g., FFPE) is provided, the method comprising: contacting a tissue sample containing a nucleic acid target with an anchoring agent, the anchoring agent comprising a first chemical portion that can react with and / or modify an internal base of the nucleic acid target (e.g., a reactive group that can form a covalent bond with the target nucleic acid) and a second chemical portion that can be incorporated into a polymer gel (e.g., a reactive group that can form a covalent bond with the polymer gel); contacting the tissue sample with an anchor probe that specifically binds (e.g., via hybridization) to the nucleic acid target ; immobilizing (e.g., via covalent attachment of the anchoring agent to the polymer gel) nucleic acid target-binding anchoring probes and nucleic acid target-binding anchoring agents in at least a portion of the tissue sample within the gel; clearing the tissue sample within the polymer gel by removing or degrading non-targets (e.g., unfixed target nucleic acids); contacting the cleared tissue sample (e.g., fixed target nucleic acid sample) with a plurality of primary oligonucleotide nucleic acid probes capable of selectively binding (e.g., hybridizing) to nucleic acid targets; detecting (e.g., via imaging) nucleic acid probes bound to fixed nucleic acid targets within the cleared (e.g., gel-embedded) tissue sample.

[0035] In certain embodiments, methods for imaging target nucleic acids from formalin-fixed paraffin-embedded (FFPE) tissue samples are provided. In embodiments, the method comprises contacting the tissue sample with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises an oligonucleotide that hybridizes with the target nucleic acid; embedding the sample in a polymer gel, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer gel; cleaning unfixed cellular components from the polymer gel to form a gel-fixed target nucleic acid sample; and contacting the fixed target nucleic acid sample with one or more primary oligonucleotide probes that hybridize with the target nucleic acid, and imaging the target nucleic acid.

[0036] In some embodiments, a cleanup step is performed after the target nucleic acid is fixed in a polymer gel (e.g., after the steps of contacting the sample with the anchor probe and the anchor agent and fixing the nucleic acid target-bound anchor probe and the nucleic acid target-bound anchor agent) and before the primary oligonucleotide probe is added to the fixed target nucleic acid. For example, in certain embodiments, the desired target is fixed in a gel (e.g., an inert gel matrix) while other components are removed or degraded.

[0037] The primary oligonucleotide probe can be, for example, a MERFISH probe or a smFISH probe, and can be substantially complementary to mRNA or other RNA, for example, for transcriptome analysis. The primary oligonucleotide probe can also include a signaling entity (e.g., a fluorescent signaling entity) for imaging and / or analysis of a sample. In certain embodiments, the secondary oligonucleotide probe hybridized with the primary oligonucleotide probe includes an imaging portion (e.g., a fluorescent signaling entity), wherein imaging includes adding one or more secondary probes. In some embodiments, the method further includes generating a code word or a bar code based on the distribution of the nucleic acid probes combined in the sample. In some embodiments, the method further includes matching the code word with a valid code word for at least some of the code word, optionally wherein if no match is found, error correction is applied to the code word to form a valid code word or to discard the code word. I. Tissue Samples

[0038] As used herein, "tissue sample" refers to a collection of similar cells obtained from a subject's tissue in this article. Tissues may contain nucleated cells with chromosomal material. The source of the tissue sample may be solid tissue such as from fresh, frozen, FFPE and / or preserved organ or tissue samples or biopsies or aspirates; or blood or any blood component; or body fluids such as cerebrospinal fluid, amniotic fluid, peritoneal fluid or interstitial fluid; or cells from any time of pregnancy or development of the subject. Tissue samples may also be primary or cultured cells or cell lines or cultured tissues. Tissue samples may contain compounds that are not naturally mixed with the tissue in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc. In some embodiments of the present invention, the tissue sample is non-blood tissue (i.e., not blood or bone marrow tissue). In embodiments, the tissue sample used in the method of the present invention is a formalin-fixed paraffin-embedded tissue sample. Although the method of the present invention can be used with any tissue sample disclosed herein, the method provides special advantages for FFPE tissue samples or any sample suspected of containing fragmented nucleic acids and / or in terms of accessible nucleic acid targets.

[0039] In an embodiment, nucleic acid fragmentation can be evaluated and measured using methods well known in the art. For example, in order to evaluate the sample quality for in situ hybridization, RNA integrity value (RIN) or DV200 value is used via commercially available instruments such as BioAnalyzer or TapeStation platforms to provide information to determine the RNA quality of the tissue block. In short, RNA is first extracted from the sample and measured on BioAnalyzer or TapeStation. RIN is represented by a value ranging from 1 to 10, wherein 1 represents that the sample has shorter and more degraded RNA, and 10 reflects longer and less degraded RNA. Higher RIN scores will have more complete 18S and 28S RNA. DV200 reflects the percentage of RNA fragments with a length greater than 200 nucleotides in the tissue sample. Tissues with a lower DV200 percentage have shorter and more degraded RNA; on the contrary, higher percentages indicate that there are longer and less degraded RNA molecules in the tissue.

[0040] In some embodiments, tissue sample is a tissue section, a clinical smear or a cultured cell or tissue. In some embodiments, tissue sample comprises a tissue section. As used herein, " section " of tissue sample herein refers to a single part or sheet of a tissue sample, for example, a thin slice of tissue or cells cut from a tissue sample. It should be understood that multiple sections of a tissue sample can be obtained and analyzed according to the present invention. In some embodiments, the selected part or section of tissue comprises a homogeneous cell population. In some embodiments, the selected part or section of tissue comprises a heterogeneous cell population. In some embodiments, the selected part comprises the region of tissue, for example, as a non-limiting example, the lumen. For example, the selected part can be as small as one cell or two cells, or can represent for example thousands of cells.

[0041] Any tissue sample from the subject can be used. Examples of tissue samples that can be used include, but are not limited to, breast, prostate, ovary, colon, lung, endometrium, stomach, salivary gland, or pancreas. Tissue samples can be obtained by a variety of procedures, including but not limited to surgical resection, aspiration, or biopsy. The tissue can be fresh or frozen.

[0042] In some embodiments, the tissue section is a tissue section of the brain, adrenal gland, colon, small intestine, stomach, heart, liver, skin, kidney, lung, pancreas, testis, ovary, prostate, uterus, thyroid and spleen of a mammal (e.g., human or mouse). The method of the present disclosure can be applied to any type of tissue, including, for example, cancer tissue (including from any cancer). In some embodiments, the tissue section is from a solid tumor. In some embodiments, the tissue sample is from the small intestine of a mouse. In some embodiments, the tissue sample is from the brain of a mouse. In some embodiments, the tissue sample is from human liver cancer. In some embodiments, the tissue sample is from human kidney. In some embodiments, the tissue sample is from human lung. In some embodiments, the tissue sample is from human ovarian cancer. In some embodiments, the tissue sample is from human uterine cancer. In some embodiments, the tissue sample is from human lung cancer.

[0043] In some embodiments, the tissue has been stored for a period of time, for example, a period of time for storing frozen or FFPE tissue. In some embodiments, the tissue sample is a frozen tissue sample. In some embodiments, the tissue is a frozen tissue. In some embodiments, the tissue is a paraffin-embedded tissue. In some embodiments, the tissue is a formalin-fixed paraffin-embedded tissue. A. Preparation of tissue samples 1. Obtaining and Fixing Tissue Samples

[0044] Tissue samples may be obtained from intact organs or tissues using any method known to those skilled in the art, such as existing methods for preparing tissue samples for immunohistochemistry (IHC) or in situ hybridization (ISH) techniques.

[0045] For example, any intact organ or tissue can be cut into relatively small pieces (the size of the cut pieces is usually in the range of a few millimeters to a few centimeters) and "fixed" to maintain the position of the nucleic acid in the sample. Techniques for fixing cells and tissues are known to those of ordinary skill in the art. Non-limiting examples of fixatives include formaldehyde, paraformaldehyde, glutaraldehyde, ethanol, methanol, acetone, acetic acid, etc.

[0046] In some embodiments, the tissue sample is fixed in a solution containing an aldehyde. In some embodiments, the tissue sample is fixed in a solution containing formalin. In some embodiments, the tissue sample is paraffin embedded. In embodiments, the tissue sample is formalin fixed and paraffin embedded (FFPE).

[0047] In addition to intact samples, other samples can be used. In some embodiments, frozen sections can be prepared by the following method: rehydrating 50 mg of frozen pulverized tissue in phosphate buffered saline (PBS) in a small plastic capsule at room temperature; pelleting the particles by centrifugation; resuspending the particles in a viscous embedding medium (OCT); inverting the capsule and / or re-precipitating by centrifugation; snap freezing in -70°C isopentane; cutting the plastic capsule and / or removing the frozen tissue cylinder; fixing the tissue cylinder on a cryostat microtome chuck; and / or cutting 25-50 consecutive sections. Similarly, permanent tissue sections can be prepared, including rehydrating 50 mg of sample in a plastic microcentrifuge tube; pelleting; resuspending in 10% formalin to fix for 4 hours; washing / precipitating; resuspending in warm 2.5% agar; pelleting; cooling in ice water to harden the agar; removing the tissue / agar block from the tube; infiltrating and / or embedding the block in paraffin; and / or cutting up to 50 consecutive permanent sections.

[0048] In some embodiments, the present invention can utilize standard frozen samples, such as those embedded in OCT and not pulverized, including, for example, those used in standard frozen section hospital laboratories.

[0049] Tissue samples are usually fixed by conventional methods. Aldehyde fixatives such as formalin (formaldehyde) and glutaraldehyde are usually used. Tissue samples fixed using other fixation techniques (such as alcohol immersion) are also suitable. See Battifora and Kopinski, J., Histochem.Cytochem., 34:1095 (1986). Those skilled in the art will understand that the choice of fixative is determined by the purpose of the tissue being histologically stained or otherwise analyzed. Those skilled in the art will also understand that the length of fixation depends on the size of the tissue sample and the fixative used.

[0050] The sample used can also be embedded in paraffin. In some embodiments, the tissue sample is fixed and embedded in paraffin, etc. In some embodiments, the tissue sample is formalin fixed and paraffin embedded. In some embodiments, the paraffin embedded (FFPE) tissue block of formalin fixation is stained with hematoxylin and eosin (H&E). As generally known in the art, the tissue sample can be fixed first, then dehydrated by a series of increasing alcohols, infiltrated and embedded with paraffin or other slice media, so that the tissue sample can be sliced. Alternatively, the tissue can be sliced ​​and the obtained slices can be fixed. For example, the tissue sample can be embedded and processed in paraffin by conventional methods. The example of usable paraffin includes but is not limited to Paraplast, Broloid and Tissuemay. After the tissue sample is embedded, the sample can be sliced ​​by a slicer, etc. After slicing, the slices can be attached to a slide by several standard methods. The example of sliding adhesive includes but is not limited to silane, gelatin, poly-L-lysine, etc. For example, paraffin-embedded sections can be attached to positively charged slides and / or slides coated with poly-L-lysine.

[0051] In some embodiments, the tissue section may be in the range of about 3 μm to about 100 μm, or any intermediate range therein. In some embodiments, the tissue section may be in the range of about 10 μm to about 100 μm. In some embodiments, the tissue section may be in the range of about 10 μm to about 50 μm. In some embodiments, the tissue section may be in the range of about 10 μm to about 30 μm. In some embodiments, the tissue section may be in the range of about 10 μm to about 15 μm. In some embodiments, the tissue section may be in the range of about 3 μm to about 15 μm. In some embodiments, the tissue section may be in the range of about 5 μm to about 20 μm. In some embodiments, the tissue section may be in the range of about 15 μm to about 30 μm. In some embodiments, the tissue section can be within the range of about 3 μm, about 4 μm, about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm, about 11 μm, about 12 μm, about 13 μm, about 14 μm, about 15 μm, or about 20 μm. In some embodiments, the tissue section can be within the range of about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, or about 100 μm. 2. Deparaffinization and Rehydration

[0052] The tissue sections can be deparaffinized using methods known in the art and / or commercially available kits. The method removes most of the paraffin from the sample. Various techniques for deparaffinization are known, and include but are not limited to washing with organic solvents or agents to dissolve the paraffin.

[0053] Exemplary deparaffinizing solvents include but are not limited to benzene, toluene, ethylbenzene, xylene, D-limonene, octane and mixtures thereof. In certain embodiments, the deparaffinizing solvent comprises D-limonene. These solvents preferably have high purity, usually greater than 99%. The volume used and the required number of washes will depend on the size of the sample and the amount of paraffin to be removed. The number of washes of the sample can be between 1 and approximately 10 times, or between approximately two and approximately four times. For a 10mm tissue sample, the typical volume of an organic solvent is approximately 500ml.

[0054] After deparaffinization, the sample can be rehydrated, such as by stepwise washing with decreasing concentrations of lower alcohol solutions. Ethanol is the preferred lower alcohol for rehydration, but other alcohols can also be used. Non-limiting examples include methanol, isopropanol, and other C1-C5 alcohols. Alternatively, the sample is vigorously mixed with an alcohol solution and then the alcohol solution is removed. In some embodiments, a dehydration system such as EZ-DEWAX TM (BioGenex, San Ramon, CA) reagents were used for simultaneous deparaffinization and rehydration.

[0055] In some embodiments, the concentration of the alcohol is gradually reduced. In some embodiments, the concentration range of the alcohol is gradually reduced from about 100% to about 70% in water in about three to five progressive steps. In some embodiments, the concentration range of the alcohol is gradually reduced in three progressive steps, respectively 100%, 90% and 70%. 3. Optional Pretreatment for Antigen Retrieval

[0056] In some embodiments of the present disclosure, the sample can be pretreated to directly or indirectly promote the method of the present invention. In some embodiments, the pretreatment of the tissue increases the availability of the target nucleic acid or other target (e.g., for cell morphology staining). Pretreatment for making the target available (e.g., repairing or exposing "antigen repair" of the target biomarker). An extensive review of antigen repair can be found in Shi et al. 1997, J Histochem Cytochem, 45 (3): 327. Antigen repair includes a variety of methods by which the availability of the target for interacting with a specific detection reagent is maximized.

[0057] The most common techniques are protease-induced epitope repair (PIER) or heat-induced epitope repair (HIER). Protease-induced epitope repair (PIER) can utilize enzymes (such as proteinase K, pepsin, trypsin, protease and any subtype thereof) in appropriate buffers to recover the epitope for antibody binding. Heat-induced epitope repair (HIER) can utilize heat to reverse some crosslinks and allow the recovery of epitopes. Citrate buffer, Tris and EDTA base can be used as exemplary heat-induced reagents (e.g., 10mM sodium citrate, 6.0pH; 1mM EDTA, pH 8.0; 10mMTris base, 1mM EDTA solution, 0.05% Tween 20, pH 9.0) in a suitable stable pH manner. Detergents (e.g., Tween20) can be added to HIER buffer to increase epitope repair. In certain aspects, many special formulations can be used for PIER or HIER-mediated antigen repair.

[0058] Selective staining can be performed on tissue sections to detect biomarkers and identify cell types (e.g., nuclear and / or cell morphology staining). In order to facilitate the specific recognition of biomarkers in fixed tissues (e.g., FFPE tissue samples after deparaffinization and rehydration), it is usually necessary to repair or expose the target biomarkers by "antigen retrieval" (also called epitope retrieval or antigen exposure). II. Target Immobilization

[0059] It should be understood that embedding tissue sample in gel matrix and fixing nucleic acid target (i.e., covalent attachment of anchoring agent to polymer gel) can be carried out in any suitable order in various embodiments, as long as they are completed before cleaning tissue sample (unfixed target nucleic acid) in gel matrix. It should also be understood that primary probe addition and hybridization occur after cleaning step. In an embodiment, anchoring agent and primary oligonucleotide probe are not added at the same time and / or in the same step. For example, the fixation of target nucleic acid can occur before or during embedding sample, but primary oligonucleotide probe is added after removing or cleaning non-target cell components from polymer gel matrix. It can be understood that the fixation of target nucleic acid is a multi-step process, wherein first anchoring agent is added to tissue sample, and covalent bond (as disclosed herein for the first anchoring agent of method) is formed between the first anchoring agent and target nucleic acid, and the second anchoring agent comprises oligonucleotide hybridized with target nucleic acid (as disclosed herein for anchoring probe or second anchoring agent of method), then contacted with polymer matrix, wherein both the first anchoring agent and the second anchoring agent form covalent bond with polymer gel. The entire process immobilizes the target nucleic acid in a polymer gel matrix.

[0060] In embodiments, the target nucleic acid anchoring agent is reacted before, during, or after formation of the polymer matrix to form a covalent bond with the polymer gel. A. Anchoring Agent

[0061] In an embodiment, at least two anchoring agents are provided for fixing a target nucleic acid (e.g., an RNA transcript) to a polymer matrix, as discussed below. In one embodiment, the first anchoring agent is functionalized to include a first chemical moiety or reactive group that will form a covalent bond with the target nucleic acid, and a second chemical moiety or reactive group that will form a covalent bond with a polymer gel matrix. In another embodiment, the second anchoring agent includes an oligonucleotide hybridized with the target nucleic acid and a chemical moiety or reactive group that will form a covalent bond with the polymer gel matrix. In certain embodiments, the chemical moiety or reactive group of the second anchoring agent is the same or different from the second chemical moiety of the first anchoring agent. In certain embodiments, due to the oligonucleotide hybridized with the target nucleic acid, the second anchoring agent is also referred to as an anchoring probe in this article. In an embodiment, the oligonucleotide portion of the second anchoring agent includes a poly-T (thymine residue) for hybridizing with the poly-A tail of an mRNA transcript.

[0062] In some embodiments, anchor probes may contain sequences that are complementary to (e.g., bind to) desired (target) nucleic acid species via base pairing (hybridization). In embodiments, anchor probes comprise a chemical moiety or reactive group that is capable of polymerizing (e.g., covalently bonding) to a polymer gel matrix.

[0063] In one set of embodiments, the anchor forms a covalent bond with the polymer gel matrix during polymerization. For example, in the case of polyacrylamide, the anchor can include an acrydite portion that can be polymerized and incorporated into the polymer. In certain embodiments, the second anchor or anchor probe comprises an oligonucleotide (poly-T) that hybridizes to the poly A tail of the mRNA and an acrydite portion that forms a covalent bond with the polyacrylamide, wherein the gel embedding step utilizes polyacrylamide.

[0064] Anchoring agent can also contain the part that can interact and combine with nucleic acid molecule or other molecules (for example, protein or lipid, other required targets, etc.) that need to be fixed therein.Fixing can be covalent or non-covalent.For example, in order to fix the target nucleic acid, anchoring agent can comprise the nucleic acid containing acrydite part (for example, at 5' end, 3' end, internal base, etc.) and the nucleic acid sequence that is substantially complementary to at least a portion of the target nucleic acid.For example, nucleic acid can be complementary to at least 5,6,7,8,9,10,11,12,13,14,15,16,17,18,19 or 20 or more nucleotides of nucleic acid.In some cases, complementarity can be accurate (Watson-Crick complementarity), or there can be 1,2 or more mispairings.In some cases, anchoring agent can be configured to fix mRNA, for example, in the case of transcriptome analysis.For example, in one group of embodiments, anchoring agent can contain multiple thymine nucleotides, for example, sequentially for binding to the poly A tail of mRNA. Thus, for example, the anchoring agent can have at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more continuous thymine nucleotides (e.g., poly-dT moieties) in the anchoring agent. In some cases, at least some thymine nucleotides can be "lock" thymine nucleotides. These can constitute at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% of these thymine nucleotides. In certain embodiments, lock nucleotides and non-lock nucleotides can alternate. Such lock thymine nucleotides can be used for example to stabilize the hybridization of the poly-A tail of mRNA with the anchoring agent.

[0065] In embodiments, the method herein further comprises the use of another anchoring agent, referred to herein as the first anchoring agent, wherein the anchoring agent is functionalized with a first chemical moiety and a second chemical moiety for covalent attachment to a target nucleic acid and a polymer gel matrix. In certain embodiments, the anchoring agent is a derivatized alkylating agent, wherein the alkylating agent has been derivatized with a chemical moiety or reactive group that will form a covalent bond with the polymer gel matrix. Alkylating agents are well known in the art, and they form covalent bonds with nucleic acids (including RNA), and any alkylating agent can be derivatized to form an anchoring agent of the present invention. In certain embodiments, the anchoring agent is an alkylating agent derivatized with a reactive group that forms a covalent bond with polyacrylamide. In certain embodiments, the anchoring agent is an alkylating agent comprising an acrydite moiety. In an embodiment, the alkylating agent is selected from altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, temozolomide, thiotepa, and trabectedin.

[0066] In embodiments, the methods of the present invention use both anchor probes and anchor agents (first anchor agent and second anchor agent) for fixing the target nucleic acid in a polymer gel matrix. In some embodiments, the nucleic acid target is fixed in the gel via both anchor probes and anchor agents bound to the nucleic acid target.

[0067] In one set of embodiments, nucleic acid molecules can be fixed by covalent bonding. For example, in one set of embodiments, an alkylating agent covalently bound to a nucleic acid molecule and containing a second chemical moiety can be used, and the second chemical moiety can be incorporated into the polyacrylamide when the polyacrylamide is polymerized. In another set of embodiments, the terminal ribose in the RNA molecule can be oxidized using sodium periodate (or another oxidant) to produce an aldehyde, which can be cross-linked to acrylamide or other polymers or gels. In other embodiments, chemicals capable of modifying bases can be used, such as aldehydes (e.g., paraformaldehyde or glutaraldehyde), alkylating agents, or groups containing succinimidyl groups; chemicals that modify terminal phosphates, such as carboimides, such as EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide); chemicals that modify internal sugars, such as p-maleimido-phenyl isocyanate; or chemicals that modify terminal sugars, such as sodium periodate. In some cases, these chemical agents may carry a second chemical moiety that can then be directly cross-linked to the gel or polymer, and / or the second chemical moiety may be further modified with a compound that can be directly cross-linked to the gel or polymer.

[0068] In yet other embodiments, nucleic acids can be immobilized using anchor probes having portions that are substantially complementary to DNA or RNA. There can be 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50 or more complementary nucleotides between the anchor probe and the nucleic acid. B. Gel Polymer Matrix

[0069] In some embodiments, the methods disclosed herein further comprise immobilizing the nucleic acid target-bound anchor probes in at least a portion of the tissue sample within a polymer gel.

[0070] Samples can be embedded in a matrix for fixing nucleic acid targets. For example, the matrix can include gel or polymers, such as polyacrylamide. Therefore, for example, acrylamide and a suitable cross-linking agent (for example, N, N'-methylenebisacrylamide) can be added to the sample and polymerized to form a gel. Anchoring probes (if present) can include a part (for example, acrydite part) that can be polymerized with the gel during the polymerization process, and nucleic acid (for example, mRNA containing poly A tail) can be associated with the anchoring part subsequently. In this way, mRNA can be fixed to polyacrylamide gel. As another example, DNA and / or RNA molecules can be fixed to polyacrylamide gel using anchoring probes with a part that is substantially complementary to DNA or RNA. As another example, DNA and / or RNA molecules can be physically entangled in polyacrylamide gel, for example, due to their length, to fix them to polyacrylamide gel.

[0071] The sample may be partially or completely fixed or embedded in a polymer or gel. In some cases, the sample may be embedded in a relatively large polymer or gel, which may then be sliced ​​or cut into thin slices to produce smaller portions for analysis, such as using various microtome techniques commonly available to those of ordinary skill in the art. For example, a tissue or organ may be fixed in a suitable polymer or gel.

[0072] Various polymers can be used in some embodiments. In some cases, relatively optically transparent polymers can be selected. Polymers can also be polymers that are not significantly deformed during polymerization, although in some cases, polymers may exhibit some deformations. In some cases, the amount of deformation can be determined as less than 5, less than 4, less than 3, less than 2, less than 1.5, less than 1.3 or less than 1.2 relative size changes (that is, the size change is 2 means that the linear size of the sample doubles), or the reciprocal of these (that is, the reciprocal of the size change is 2 means that the linear size of the sample is halved).

[0073] Examples of suitable polymers include polyacrylamide and agarose. In embodiments, the polymer is not a hydrogel and / or does not include a polymer or monomer that swells or expands. In various embodiments involving chemical crosslinking between gel subunits, a variety of polymers can be used, including but not limited to acrylic acid, acrylamide, ethylene glycol diacrylate, ethylene glycol dimethacrylate, poly (ethylene glycol dimethacrylate); and / or hydrophobic or hydrogen bonding interactions, such as poly (N-isopropylacrylamide), methylcellulose, (ethylene oxide)-(propylene oxide)-(ethylene oxide) terpolymers, sodium alginate, poly (vinyl alcohol), alginate, chitosan, gum arabic, gelatin and agarose. III. Tissue Cleaning

[0074] After the nucleic acid target is immobilized to the gel, other components within the sample that are not the desired target (eg, unimmobilized target nucleic acid) may be removed or degraded.

[0075] "Clearing" tissue sample or "cleaned" tissue sample means making the tissue sample substantially light-transmissive, i.e. transparent, and the optical properties of the sample change to allow more light to pass through the sample. In some embodiments, about 70% or more of the light (e.g., white light, ultraviolet light, or infrared light) used to illuminate the sample will pass through the sample and only illuminate the selected cell components (e.g., nucleic acids) therein, for example, 75% or more of the light, 80% or more of the light, 85% or more of the light, 90% or more of the light, 95% or more of the light, 98% or more of the light, for example, 100% or more of the light will pass through the sample. In the methods described herein, any treatment known for tissue cleaning can be used to clean up the tissue sample, which will be discussed further below.

[0076] The details of tissue cleaning are further discussed in U.S. Patent Publication No. 2019 / 0264270 entitled "Matrix Imprinting and Clearing" published on August 29, 2019, the contents of which are incorporated herein by reference in their entirety. Such cleaning can include removing (e.g., physically removing) cellular components from the sample, and / or degrading cellular components within the sample so that they no longer stand out within the background. Degradation can include, for example, chemical degradation, enzymatic degradation, etc.

[0077] In some cases, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% of the unwanted components within the sample can be removed or degraded. Such cleaning can include physical removal or degradation of components (e.g., degradation to smaller components, non-luminescent components, etc.). Removal or degradation of such components can reduce background fluorescence or autofluorescence within the sample during analysis.

[0078] In certain embodiments, multiple cleanup steps may also be performed, for example, to remove or degrade various undesirable components.

[0079] For example, enzymes, denaturants, chelating agents, chemicals, etc. can break down proteins into smaller components and / or amino acids. These smaller components can be more easily physically removed, and / or can be small or inert enough so that they do not significantly affect the background. Similarly, surfactants, etc. can be used to remove or degrade lipids from samples. In some cases, for example, one or more of these are used simultaneously or sequentially. Non-limiting examples of suitable enzymes include proteases such as proteinase K, proteases or peptidases, or digestive enzymes such as trypsin, pepsin or chymotrypsin. Non-limiting examples of suitable denaturants include guanidine hydrochloride, acetone, acetic acid, urea or lithium perchlorate. Non-limiting examples of chemicals that can denature proteins include solvents such as phenol, chloroform, guanidine isocyanate, urea, formamide, etc. Non-limiting examples of surfactants include Triton X-100 (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether), SDS (sodium dodecyl sulfate), Igepal CA-630 or poloxamer. Non-limiting examples of chelating agents include ethylenediaminetetraacetic acid (EDTA), citrate, or polyaspartic acid. In some embodiments, compounds such as these can be applied to samples to remove or degrade proteins, lipids, and / or other components. For example, a buffer solution (e.g., containing Tris or tris(hydroxymethyl)aminomethane) can be applied to the sample and then removed.

[0080] The non-limiting examples of the technology of removing or degrading RNA include RNases such as RNase A, RNase T or RNase H, or chemicals such as via alkaline hydrolysis (e.g., by increasing the pH to greater than 10). The non-limiting examples of systems for removing or degrading sugar or extracellular matrix include enzymes, such as chitinase, heparinase or other glycosylases. The non-limiting examples of systems for removing or degrading lipids include enzymes (e.g., lipases), chemicals (e.g., alcohols (e.g., methanol or ethanol)) or detergents (e.g., Triton X-100 or sodium lauryl sulfate). Many of these are easily commercially available. In this way, the background of the sample can be reduced, which can promote the analysis of nucleic acid probes or other desired targets, such as using fluorescence microscopy or other techniques as discussed herein. IV. Formation of Nucleic Acid Target / Probe Complex A. Nucleic acid targets

[0081] The nucleic acid target can be, for example, DNA, RNA, or other nucleic acid present in cells within a tissue sample.

[0082] In some embodiments, the nucleic acid target is RNA. RNA can be coding and / or non-coding RNA. Non-limiting examples of RNA in cells that can be studied include mRNA, siRNA, rRNA, miRNA, tRNA, lncRNA, snoRNA, snRNA, exRNA, piRNA, etc.

[0083] The nucleic acid can be endogenous to the cell, or added to the cell. For example, the nucleic acid can be viral or artificially produced. In some cases, the nucleic acid to be determined can be expressed by the cell.

[0084] In some cases, a significant portion of the nucleic acid in a cell can be studied. For example, in some cases, sufficient RNA present in a cell can be determined to generate a partial or complete transcriptome of the cell. In some cases, at least 4 unique mRNA gene transcripts in a cell are determined, and in some cases, at least 3, at least 4, at least 7, at least 8, at least 12, at least 14, at least 15, at least 16, at least 22, at least 30, at least 31, at least 32, at least 50, at least 63, at least 64, at least 72, at least 75, at least 100, at least 127, at least 128, at least 140, at least 255, at least 256, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 100, at least 127, at least 128, at least 140, at least 255, at least 256, at least 57, at least 58, at least 59 At least 1,000, at least 1,500, at least 2,000, at least 2,500, at least 3,000, at least 4,000, at least 5,000, at least 7,500, at least 10,000, at least 12,000, at least 15,000, at least 20,000, at least 25,000, at least 30,000, at least 40,000, at least 50,000, at least 75,000, or at least 100,000 types of mRNA.

[0085] In some cases, the transcriptome of the cell can be determined. It should be understood that the transcriptome generally encompasses all RNA transcript molecules produced in the cell, both coding and non-coding, rather than just coding messenger RNA. Therefore, for example, the transcriptome can also include non-coding rRNA, tRNA, siRNA, miRNA, etc. In some embodiments, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or 100% of the transcriptome of the cell can be determined.

[0086] The determination of one or more nucleic acids in a sample can be qualitative and / or quantitative. In addition, the determination can also be spatial, for example, the position of nucleic acids in a sample can be determined in two dimensions or three dimensions. In some embodiments, the position, quantity and / or concentration of nucleic acids in a cell (or other samples) can be determined. B. Nucleic acid probe

[0087] In one set of embodiments, as an illustrative, non-limiting example, a target nucleic acid sample that has been cleared of non-target cellular components and fixed (a "matrix-anchored target nucleic acid sample") can be studied by exposing it to one or more types of primary oligonucleotide nucleic acid probes, which can be imaged simultaneously or sequentially with secondary nucleic acid probes (e.g., fluorescently labeled).

[0088] For example, in one set of embodiments, the nucleic acid probe can include a smFISH or MERFISH probe, such as those discussed in US Pat. No. 11,098,303 or US Pat. No. 10,240,146, each of which is incorporated herein by reference in its entirety.

[0089] The nucleic acid probe may comprise a nucleic acid (or an entity that can, for example, specifically hybridize with a nucleic acid), such as DNA, RNA, LNA (locked nucleic acid), PNA (peptide nucleic acid) or a combination thereof. In some cases, additional components may also be present in the nucleic acid probe, for example, as discussed below. Any suitable method may be used to introduce the nucleic acid probe into the sample.

[0090] After removing non-target cell components from the gel, the nucleic acid probe is added to the sample containing the target nucleic acid fixed by the gel.Some aspects of the present invention generally relate to the nucleic acid probe introduced into the sample.Depending on the application, the probe can include any of a variety of entities that can be hybridized with nucleic acids by Watson-Crick base pairing, such as DNA, RNA, LNA, PNA, etc. The nucleic acid probe generally contains a target sequence that can be combined with at least a portion of the target nucleic acid (in some cases, specific binding).When introduced into the sample, the nucleic acid probe can be combined with a specific target nucleic acid (for example, mRNA or other nucleic acids as discussed herein).In some cases, the nucleic acid probe can be measured using a signaling entity (for example, as discussed below) and / or by using a secondary nucleic acid probe that can be combined with the nucleic acid probe (that is, with a primary nucleic acid probe).The determination of such nucleic acid probes is discussed in detail below.

[0091] In some cases, more than one different (primary) nucleic acid probe can be applied to a sample, for example, simultaneously. For example, there can be at least 2, at least 5, at least 10, at least 25, at least 50, at least 75, at least 100, at least 300, at least 1,000, at least 3,000, at least 10,000, at least 30,000, at least 50,000, at least 100,000, at least 250,000, at least 500,000 or at least 1,000,000 distinguishable nucleic acid probes, for example, applied to a sample simultaneously or sequentially.

[0092] In certain embodiments, the primary oligonucleotide probe comprises a target sequence designed to hybridize with the target nucleic acid of anchoring. The target sequence can be located at any position in the nucleic acid probe (or primary nucleic acid probe or encoding nucleic acid probe). The target sequence can contain a region that is substantially complementary to a part of the target nucleic acid. In some cases, part can be at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary. In some cases, the target sequence can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides in length. In some cases, the target sequence can be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, no more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides in length. Combinations of any of these are also possible, for example, the target sequence can have a length of between 10 and 30 nucleotides, between 20 and 40 nucleotides, between 5 and 50 nucleotides, between 10 and 200 nucleotides, or between 25 and 35 nucleotides, between 10 and 300 nucleotides, etc. Typically, complementarity is determined based on Watson-Crick nucleotide base pairing.

[0093] The target sequence of a (primary) nucleic acid probe can be determined with reference to a target nucleic acid suspected of being present in a sample. For example, the sequence of a protein can be used to determine the target nucleic acid of the protein by measuring the nucleic acid expressed to form the protein. In some cases, only a portion of the nucleic acid encoding the protein is used, for example, with a length as discussed above. In addition, in some cases, more than one target sequence that can be used to identify a specific target can be used. For example, multiple probes can be used sequentially and / or simultaneously, which can be combined or hybridized with different regions of the same target. Hybridization generally refers to an annealing process, by which complementary single-stranded nucleic acids are associated to form double-stranded nucleic acids by Watson-Crick nucleotide base pairing (for example, hydrogen bonding, guanine-cytosine and adenine-thymine).

[0094] In some embodiments, nucleic acid probes (such as primary nucleic acid probes) may also include one or more "reading" sequences, which are designed to hybridize with secondary nucleic acid probes comprising labels (such as fluorescent labels). However, it should be understood that reading sequences are not necessary in all cases. In some embodiments, nucleic acid probes may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or more, 20 or more, 32 or more, 40 or more, 50 or more, 64 or more, 75 or more, 100 or more, 128 or more reading sequences. Reading sequences may be located at any position in the nucleic acid probe. If there is more than one reading sequence, the reading sequences may be located adjacent to each other, and / or dispersed in other sequences. In certain embodiments, primary oligonucleotide probes include one reading sequence. In certain other embodiments, primary oligonucleotide probes include two reading sequences, which may be identical or different from each other (e.g., meaning that secondary nucleic acid probes will not hybridize with different reading sequences).

[0095] The read sequence, if present, can be of any length. If more than one read sequence is used, the read sequences can independently have the same or different lengths. In some cases, the read sequence can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60, at least 65, at least 75, at least 100, at least 125, at least 150, at least 175, at least 200, at least 250, at least 300, at least 350, at least 400, or at least 450 nucleotides in length. In some cases, the length of the read sequence can be no more than 500, no more than 450, no more than 400, no more than 350, no more than 300, no more than 250, no more than 200, no more than 175, no more than 150, no more than 125, no more than 100, no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20, or no more than 10 nucleotides. Any combination of these is also possible, for example, the read sequence can have a length of between 10 and 30 nucleotides, between 20 and 40 nucleotides, between 5 and 50 nucleotides, between 10 and 200 nucleotides, or between 25 and 35 nucleotides, between 10 and 300 nucleotides, etc.

[0096] In some embodiments, the read sequence can be arbitrary or random. In some cases, the read sequence is selected to reduce or minimize the homology with other components of the sample, for example, so that the read sequence itself is not combined or hybridized with other nucleic acids suspected to be in the sample. In some cases, the homology can be less than 10%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2% or less than 1%. In some cases, there may be less than 20 base pairs, less than 18 base pairs, less than 15 base pairs, less than 14 base pairs, less than 13 base pairs, less than 12 base pairs, less than 11 base pairs or less than 10 base pairs of homology. In some cases, the base pairs are sequential.

[0097] In certain embodiments, primary oligonucleotide probes are provided as probe pools, wherein each nucleic acid probe pool is hybridized with different target nucleic acid sequences (e.g., different RNA transcripts). In embodiments, each probe pool is assigned to the N-bit binary code of each different RNA transcript via reading sequence encoding. In certain embodiments, the N-bit binary code has at least 2, at least 4, at least 5, at least 6, at least 7, or at least 8 Hamming weights, wherein the Hamming weight value is the number of "1" values ​​in the N-bit code, and all other positions are "0". In embodiments, the N-bit binary code has at least 2 or at least 4 Hamming weights, meaning that the code contains two or four "1" bit values, respectively, and other bit positions are "0". In embodiments, the N-bit binary code has an N value of 3 to 100, wherein any value is possible. In certain embodiments, the binary code is a 4-bit binary code, a 6-bit binary code, an 8-bit binary code, a 16-bit binary code, a 36-bit binary code, a 50-bit binary code, a 54-bit binary code, or a 100-bit binary code or any combination thereof. Each position of the binary code is either a "0" or a "1", wherein the binding of the secondary probe to the read sequence determines whether the hybridization read is a "0" (where no probe binds) or a "1" (where the secondary probe binds to the read sequence of the primary probe). Sequential hybridization and imaging of the secondary read probes is performed until each position of the N-bit binary code has been read, thereby providing a barcode or codeword for the target nucleic acid (e.g., mRNA sequence).

[0098] In one group of embodiments, the nucleic acid probe colony can contain a certain number of read sequences, and in some cases, the number can be less than the number of targets of the nucleic acid probe. It will be appreciated by those of ordinary skill in the art that if there is a signaling entity and n read sequences, 2n-1 different nucleic acid targets can generally be uniquely identified. However, it is not necessary to use all possible combinations. For example, the nucleic acid probe colony can target 12 different nucleic acid sequences, but contains no more than 8 read sequences. As another example, the nucleic acid colony can target 140 different nucleic acid species, but contains no more than 16 read sequences. Different nucleic acid sequence targets can be identified individually by using different combinations of read sequences in each probe. For example, each probe can contain 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 read sequences, etc., or more read sequences. In some cases, the nucleic acid probe colony can each contain the same number of read sequences, but in other cases, different numbers of read sequences can be present on different probes.

[0099] As a non-limiting example, a first nucleic acid probe can contain a first target sequence, a first read sequence, and a second read sequence, while a second, different nucleic acid probe can contain a second target sequence, the same first read sequence, but a third read sequence instead of the second read sequence. As discussed herein, such probes can thus be distinguished by determining the various read sequences present at or associated with a given probe or position.

[0100] Furthermore, in certain embodiments, nucleic acid probes (and their corresponding complementary sites on coding probes) can be prepared using only 2 or only 3 of the 4 bases, such as excluding all Gs or excluding all Cs within the probe. In certain embodiments, sequences lacking Gs or Cs can form very little secondary structure and can facilitate more uniform and faster hybridization.

[0101] In some embodiments, the nucleic acid probe may contain a signaling entity. However, it should be understood that a signaling entity is not required in all cases; for example, in some embodiments, a secondary nucleic acid probe may be used to determine the nucleic acid probe, as discussed in further detail below. Examples of signaling entities that can be used are also discussed in more detail below.

[0102] Other components may also be present in the nucleic acid probe. For example, in one group of embodiments, one or more primer sequences may be present, for example to allow enzymatic amplification of the probe. One of ordinary skill in the art will know primer sequences suitable for applications such as amplification (e.g., using PCR or other suitable techniques). Many such primer sequences are commercially available. Other examples of sequences that may be present in the primary nucleic acid probe include, but are not limited to, promoter sequences, operators, identification sequences, nonsense sequences, etc.

[0103] In some embodiments, primers are single-stranded or partially double-stranded nucleic acids (e.g., DNA), which are used as the starting point for nucleic acid synthesis, allowing polymerases such as nucleic acid polymerases to extend primers and replicate complementary strands. Primers are (e.g., designed to) be complementary to target nucleic acids and hybridize with target nucleic acids. In some embodiments, primers are synthetic primers. In some embodiments, primers are non-naturally occurring primers. Primers generally have a length of 10 to 50 nucleotides. For example, primers can have a length of 10 to 40, 10 to 30, 10 to 20, 25 to 50, 15 to 40, 15 to 30, 20 to 50, 20 to 40, or 20 to 30 nucleotides. In some embodiments, primers have a length of 18 to 24 nucleotides.

[0104] In addition, the components of the nucleic acid probe can be arranged in any suitable order. For example, in one embodiment, the components can be arranged in the nucleic acid probe as: primer-reading sequence-targeting sequence-reading sequence-reverse primer. The "reading sequences" in this structure can each contain any number (including 0) of reading sequences, as long as at least one reading sequence is present in the probe. Non-limiting examples of structures include: Primer-targeting sequence-reading sequence-reverse primer, Primer-reading sequence-targeting sequence-reverse primer, ·Targeting sequence-primer-targeting sequence-reading sequence-reverse primer, · Targeting sequence-primer-reading sequence-targeting sequence-reverse primer, Primer-target sequence-reading sequence-targeting sequence-reverse primer, Target sequence-primer-reading sequence-reverse primer, Target sequence - Read sequence - Primer, Read sequence-target sequence-primer, Read sequence-primer-target sequence-reverse primer, etc. Furthermore, in some embodiments, including in all of the above examples, a reverse primer is optional. V. Detection / Imaging of Nucleic Acid Target / Probe Complexes

[0105] According to certain aspects of the invention, after the primary nucleic acid probe is introduced into the sample, the nucleic acid probe can be directly measured by measuring the signaling entity (if present), and / or the nucleic acid probe can be measured by using one or more secondary nucleic acid probes (also referred to as read-out probes in this article). As mentioned, in some cases, the determination can be spatial, such as in two or three dimensions. In addition, in some cases, the determination can be quantitative, for example, the amount or concentration of the primary nucleic acid probe (and target nucleic acid) can be determined. In addition, depending on the application, the secondary probe can include any of a variety of entities that can hybridize with nucleic acids (such as DNA, RNA, LNA and / or PNA, etc.). The signaling entity is discussed in more detail below.

[0106] The secondary nucleic acid probe may contain a recognition sequence that can bind or hybridize to the read sequence of the primary nucleic acid probe. In some cases, the binding is specific, or the binding may cause the recognition sequence to preferentially bind or hybridize to only one of the read sequences present. The secondary nucleic acid probe may also contain one or more signaling entities. If more than one secondary nucleic acid probe is used, the signaling entities may be the same or different. In an embodiment, the secondary nucleic acid probe comprises a fluorescent marker and may be referred to herein as a fluorescent secondary nucleic acid probe.

[0107] Recognition sequence can have any length, and multiple recognition sequences can have identical or different lengths.If use more than one recognition sequence, recognition sequence can have identical or different lengths independently.For example, the length of recognition sequence can be at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40 or at least 50 nucleotides.In some cases, the length of recognition sequence can be no more than 75, no more than 60, no more than 65, no more than 60, no more than 55, no more than 50, no more than 45, no more than 40, no more than 35, no more than 30, no more than 20 or no more than 10 nucleotides.Any combination in these is also possible, for example, recognition sequence can have following length: between 10 and 30 nucleotides, between 20 and 40 nucleotides or between 25 and 35 nucleotides, etc.In one embodiment, recognition sequence has identical length with read sequence. In addition, in some cases, the recognition sequence can be at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% complementary to the reading sequence of the primary nucleic acid probe.

[0108] As mentioned, in some cases, the secondary nucleic acid probe can include one or more signaling entities. Examples of signaling entities are discussed in more detail below.

[0109] As discussed, in certain aspects of the invention, nucleic acid probes containing various "read sequences" are used. For example, a population or pool of primary nucleic acid probes can contain a specific "read sequence" that can bind to a specific secondary nucleic acid probe, and the location of the primary nucleic acid probe within the sample is determined using the secondary nucleic acid probe (e.g., which contains a signaling entity). As mentioned, in some cases, populations of read sequences can be combined in various combinations to generate different nucleic acid probes, for example, so that a relatively small number of read sequences can be used to generate a relatively large number of different nucleic acid probes.

[0110] Therefore, in some cases, the population of primary nucleic acid probes (or other nucleic acid probes) can each contain a certain number of read sequences, some of which are shared between different primary nucleic acid probes, so that the total population of primary nucleic acid probes can contain a certain number of read sequences. The population of nucleic acid probes can have any suitable number of read sequences. For example, the population of primary nucleic acid probes can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 read sequences, etc. In some embodiments, more than 20 are also possible. In addition, in some cases, a population of nucleic acid probes can have a total of 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 20 or more, 24 or more, 32 or more, 40 or more, 50 or more, 60 or more, 64 or more, 100 or more, 128 or more possible read sequences present, etc., although some or all of the probes may each contain more than one read sequence, as discussed herein. In addition, in some embodiments, the population of nucleic acid probes can have no more than 100, no more than 80, no more than 64, no more than 60, no more than 50, no more than 40, no more than 32, no more than 24, no more than 20, no more than 16, no more than 15, no more than 14, no more than 13, no more than 12, no more than 11, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3 or no more than two read sequences present. Any combination of these is also possible, for example, the population of nucleic acid probes can include a total of between 10 and 15 read sequences.

[0111] As a non-limiting example of a method for generating a relatively large number of nucleic acid probes from a relatively small number of read sequences, in a population of 6 different types of nucleic acid probes, each nucleic acid probe comprising one or more read sequences, the total number of read sequences within the population may be no greater than 4. It should be understood that although 4 read sequences are used in this example for ease of explanation, in other embodiments, a larger number of nucleic acid probes may be implemented depending on the application, for example, using 5, 8, 10, 16, 32 read sequences, etc., or more read sequences, or any other suitable number of read sequences described herein. If each primary nucleic acid probe contains two different read sequences, up to 6 probes may be individually determined by using 4 such read sequences (A, B, C, and D). It should be noted that in this example, the ordering of the read sequences on the nucleic acid probes is not important, i.e., "AB" and "BA" may be considered synonymous (but in other embodiments, the ordering of the read sequences may be important, and "AB" and "BA" may not necessarily be synonymous). Similarly, if 5 read sequences (A, B, C, D, and E) are used in the population of primary nucleic acid probes, up to 10 probes can be individually determined. For example, one of ordinary skill in the art will understand that for k read sequences in a population with n read sequences on each probe, up to x different probes can be generated, assuming that the ordering of the read sequences is not important; because not all probes need to have the same number of read sequences, and not all combinations of read sequences need to be used in every embodiment, more or less than this number of different probes can also be used in certain embodiments. In addition, it should also be understood that in some embodiments, the number of read sequences on each probe does not have to be the same. For example, some probes may contain 2 read sequences, while other probes may contain 3 read sequences.

[0112] In some aspects, the read sequence and / or binding pattern of the nucleic acid probe in the sample can be used to define error detection and / or error correction codes, for example, to reduce or prevent misidentification or errors of nucleic acids. Thus, for example, if binding is indicated (e.g., as determined using a signaling entity), a position can be identified with "1"; on the contrary, if no binding is indicated, a position can be identified with "0" (or in some cases, vice versa), when a primary nucleic acid probe pool comprising a read sequence is used, wherein each probe pool encodes an N-bit binary code having a Hamming weight of at least 2 via a read sequence, which is assigned to each different target nucleic acid (e.g., RNA transcript). Multiple rounds of binding assays (e.g., using different nucleic acid probes) can then be used to create, for example, a "codeword" for the spatial position based on the binding of the read probe to the read sequence of the primary probe. In some embodiments, the N-bit binary code can be subject to error detection and / or correction. For example, the codewords can be arranged so that if no match is found for a given set of read sequences or binding patterns of nucleic acid probes, the match can be identified as an error, and, optionally, error correction can be applied to the sequence to determine the correct target for the nucleic acid probe. In some cases, a codeword can have fewer "letters" or positions than the total number of nucleic acids encoded by the codeword, for example, where each codeword encodes a different nucleic acid.

[0113] Such error detection and / or error correction codes can take various forms. In other contexts such as the telecommunications industry, various such codes have been previously developed, such as Golay codes or Hamming codes. In one group of embodiments, the read sequence or binding pattern of the nucleic acid probes is assigned so that not every possible combination is assigned.

[0114] For example, if 4 read sequences are possible and a primary nucleic acid probe contains 2 read sequences, up to 6 primary nucleic acid probes can be identified; however, the number of primary nucleic acid probes used can be less than 6. Similarly, for k read sequences in a population with n read sequences on each primary nucleic acid probe, different probes can be generated, but the number of primary nucleic acid probes used can be any number greater or less than k. In addition, these can be randomly assigned, or assigned in a specific manner to increase the ability to detect and / or correct errors.

[0115] As another example, if multiple rounds of nucleic acid probes are used, the number of rounds can be arbitrarily selected. If in each round, each target can give two possible results, such as being detected or not detected, then for n rounds of probes, up to 2n different targets are possible, but the number of nucleic acid targets actually used can be any number less than 2n. For example, if in each round, each target can give more than two possible results, such as being detected in different color channels, then for n rounds of probes, more than 2n (e.g., 3n, 4n ...) different targets are possible. In some cases, the number of nucleic acid targets actually used can be any number less than this number. In addition, these can be randomly assigned, or assigned in a particular manner, to increase the ability to detect and / or correct errors.

[0116] For example, in one set of embodiments, codewords or nucleic acid probes can be allocated in the code space so that the allocation is separated by a Hamming distance, which measures the number of incorrect "reads" in a given pattern that cause nucleic acid probes to be misinterpreted as different valid nucleic acid probes. The Hamming weight refers to the distance between the N-bit binary code assigned to the target and each primary oligonucleotide probe pool encoded by its read sequence. In an embodiment, the primary probe pool can have an N-bit binary code assigned, wherein the Hamming weight is at least 4, and the Hamming weight between each pool is 4. In this embodiment, errors can be detected and corrected. In some cases, the Hamming distance can be at least 2, at least 3, at least 4, at least 5, at least 6, and so on. In addition, in one set of embodiments, the allocation can be formed as a Hamming code, for example, a Hamming (7, 4) code, a Hamming (15, 11) code, a Hamming (31, 26) code, a Hamming (63, 57) code, a Hamming (127, 120) code, and so on. In another set of embodiments, the allocation may form a SECDED code, such as a SECDED (8, 4) code, a SECDED (16, 4) code, a SECDED (16, 11) code, a SCEDED (22, 16) code, a SCEDED (39, 32) code, a SCEDED (72, 64) code, etc. In yet another set of embodiments, the allocation may form an extended binary Golay code, a perfect binary Golay code, or a ternary Golay code. In another set of embodiments, the allocation may represent a subset of possible values ​​taken from any of the above codes.

[0117] For example, a code having the same error correction properties as the SECDED code can be formed by encoding the target using only binary words containing a fixed number (e.g., 4) of "1" bits. In another set of embodiments, for the purpose of addressing asymmetric read errors, the distribution can represent a subset of possible values ​​obtained from the above code. For example, in some cases, when the ratio of "0" being measured as "1" or "1" being measured as "0" is different, a code (in which the number of "1" bits can be fixed for all binary words used) can eliminate biased measurements of words with different numbers of "1".

[0118] Therefore, in some embodiments, after determining the codeword (e.g., as discussed herein), the codeword can be compared with a known nucleic acid codeword. If a match is found, the nucleic acid target can be identified or determined. If a mismatch is found, the error in the reading of the codeword can be identified. In some cases, error correction can also be applied to determine the correct codeword, and thus the correct identity of the nucleic acid target is generated. In some cases, the codeword can be selected so that assuming that there is only one error, only one possible correct codeword is available, and therefore only one correct nucleic acid target identity is possible. In some cases, this can also be extended to a larger codeword spacing or Hamming distance; for example, a codeword can be selected so that if there are two, three or four errors (or more errors in some cases), only one possible correct codeword is available, and therefore, only one correct nucleic acid target identity is possible.

[0119] The error correction code may be a binary error correction code, or it may be based on other numbering systems, such as a ternary or quaternary error correction code. For example, in one set of embodiments, more than one type of signaling entity may be used and assigned different numbers within the error correction code. Thus, as a non-limiting example, a first signaling entity (or in some cases, more than one signaling entity) may be assigned a "1", and a second signaling entity (or in some cases, more than one signaling entity) may be assigned a "2" (where "0" indicates that no signaling entity is present), and the distributed codewords are used to define a ternary error correction code. Similarly, a third signaling entity may additionally be assigned a "3" to produce a quaternary error correction code, and so on.

[0120] The contents of each of the following references are incorporated herein by reference: U.S. Patent No. 11,098,303, entitled “Systems and Methods for Determining Nucleic Acids”; U.S. Patent No. 10,240,146, entitled “Probe Library Construction”; U.S. Patent Publication No. 2019-0264270, entitled “Matrix Imprinting and Clearing”; and U.S. Patent Publication No. 2022-0064697, entitled “Amplification methods and systems for MERFISH and other applications” for a discussion of multiplexed error-robust fluorescent in situ hybridization (MERFISH) and examples thereof (e.g., MERFISH probes, signal amplification, assaying nucleic acid probes, creating codewords, and error detection and correction, etc., described herein).

[0121] As described above, in certain aspects, a signaling entity is determined, e.g., to determine a nucleic acid probe and / or create a codeword. In some cases, a variety of techniques can be used, e.g., to spatially determine a signaling entity within a sample. In some embodiments, the signaling entity can be fluorescent, and techniques for determining fluorescence within a sample (e.g., fluorescence microscopy or confocal microscopy) can be used to spatially identify the location of the intracellular signaling entity. In some cases, the location of the entity in the sample can be determined in two or even three dimensions. In addition, in some embodiments, more than one signaling entity (e.g., signaling entities with different colors or emissions) can be determined at once and / or sequentially.

[0122] In addition, in some embodiments, the confidence level of the identified nucleic acid target can be determined. For example, the ratio of the number of exact matches to the number of matches with one or more single-bit errors can be used to determine the confidence level. In some cases, only the matching with a confidence ratio greater than a specific value can be used. For example, in certain embodiments, only when the confidence ratio of the match is greater than about 0.01, greater than about 0.03, greater than about 0.05, greater than about 0.1, greater than about 0.3, greater than about 0.5, greater than about 1, greater than about 3, greater than about 5, greater than about 10, greater than about 30, greater than about 50, greater than about 100, greater than about 300, greater than about 500, greater than about 1000 or any other suitable value, matching can be accepted. Furthermore, in some embodiments, a match is accepted only if the confidence ratio for the identified nucleic acid target is approximately 0.01, about 0.03, about 0.05, about 0.1, about 0.3, about 0.5, about 1, about 3, about 5, about 10, about 30, about 50, about 100, about 300, about 500, about 1000, or any other suitable value over that of an internal standard or false positive control.

[0123] In some embodiments, the spatial position of an entity (and, therefore, a nucleic acid probe with which the entity may be associated) can be determined at a relatively high resolution. For example, the position can be determined at a spatial resolution of more than about 100 microns, more than about 30 microns, more than about 10 microns, more than about 3 microns, more than about 1 micron, more than about 800 nm, more than about 600 nm, more than about 500 nm, more than about 400 nm, more than about 300 nm, more than about 200 nm, more than about 100 nm, more than about 90 nm, more than about 80 nm, more than about 70 nm, more than about 60 nm, more than about 50 nm, more than about 40 nm, more than about 30 nm, more than about 20 nm, or more than about 10 nm, etc.

[0124] There are a variety of techniques that can optically determine the spatial location of an entity or target or image an entity or target, such as using fluorescence microscopy, using radioactivity, via conjugation with a suitable chromophore, etc. For example, various conventional microscopy techniques that can be used in various embodiments of the present invention include, but are not limited to, epifluorescence microscopy, total internal reflection microscopy, highly inclined thin illumination (HILO) microscopy, light sheet microscopy, scanning confocal microscopy, scanning line confocal microscopy, spinning disk confocal microscopy, or other comparable conventional microscopy techniques.

[0125] In some embodiments, in situ hybridization (ISH) techniques for labeling nucleic acids such as DNA or RNA can be used, for example, in the case where a nucleic acid probe can hybridize with a nucleic acid in a sample. These can be performed, for example, at a cell scale or at a single molecule scale resolution. In some cases, an ISH probe can be composed of RNA, DNA, PNA, LNA, other synthetic nucleotides, etc. and / or any combination of these. The presence of a hybridization probe can be measured, for example, in the following manner: radioactivity, using a radiolabeled nucleic acid probe; immunohistochemistry, using, for example, a biotin-labeled nucleic acid probe; enzymatic chromophores and fluorophores are produced, using, for example, probes that can bind enzymes such as horseradish peroxidase; and methods such as tyramide signal amplification, fluorescence imaging using a nucleic acid probe directly labeled with a fluorophore, or hybridization of a secondary nucleic acid probe with these primary probes, wherein the secondary probe is detected via any of the above methods.

[0126] In some cases, the spatial position can be determined with super-resolution or with a resolution better than the wavelength or diffraction limit of light (but in other embodiments, super-resolution is not required). Non-limiting examples include STORM (stochastic optical reconstruction microscopy), STED (stimulated emission depletion microscopy), NSOM (near-field scanning optical microscopy), 4Pi microscopy, SIM (structured illumination microscopy), SMI (spatially modulated illumination) microscopy, RESOLFT (reversible saturated optical linear fluorescence transition microscopy), GSD (ground state depletion microscopy), SSIM (saturated structured illumination microscopy), SPDM (spectral precision distance microscopy), photoactivated localization microscopy (PALM), fluorescence photoactivated localization microscopy (FPALM), LIMON (3D optical microscopy nanoscale microscopy), super-resolution optical fluctuation imaging (SOFI), etc. See, for example, U.S. Pat. No. 7,838,302 to Zhuang et al., entitled “Sub-Diffraction Limit Image Resolution and Other Imaging Techniques,” issued on November 23, 2010; U.S. Pat. No. 8,564,792 to Zhuang et al., entitled “Sub-diffraction Limit Image Resolution in Three Dimensions,” issued on October 22, 2013; or WO 2013 / 090360 to Zhuang et al., entitled “High Resolution Dual-Objective Microscopy,” published on June 20, 2013, each of which is incorporated herein by reference in its entirety.

[0127] In one embodiment, the sample can be illuminated by a single Gaussian mode laser line. In some embodiments, the illumination profile can be flattened by passing these laser lines through a multimode optical fiber that is vibrated via a piezoelectric or other mechanical device. In some embodiments, the illumination profile can be flattened by passing a single mode Gaussian beam through various refractive beam shapers (such as a piShaper or a series of stacked Powell prisms). In yet another set of embodiments, the Gaussian beam can pass through a variety of different diffusing elements (such as frosted glass or a modified diffuser), which in some cases can be rotated at high speed to remove residual laser speckle. In yet another embodiment, the laser illumination can pass through a series of lenslet arrays to produce overlapping illumination images that approximate a flat illumination field.

[0128] In some embodiments, the centroid of the spatial location of an entity can be determined. For example, an image analysis algorithm known to one of ordinary skill in the art can be used to determine the centroid of a signaling entity within an image or a series of images. In some cases, an algorithm can be selected to determine non-overlapping single emitters and / or partially overlapping single emitters in a sample. Non-limiting examples of suitable techniques include maximum likelihood algorithms, least squares algorithms, Bayesian algorithms, compressed sensing algorithms, and the like. Combinations of these techniques may also be used in some cases.

[0129] In addition, the signaling entity can be inactivated in some cases. For example, in some embodiments, a first secondary nucleic acid probe containing a signaling entity can be applied to a sample that can recognize a first read sequence, and then the first secondary nucleic acid probe can be inactivated before applying a second secondary nucleic acid probe to the sample. If multiple signaling entities are used, the signaling entities can be inactivated using the same or different techniques, and some or all of the multiple signaling entities can be inactivated, for example, sequentially or simultaneously.

[0130] Inactivation can be caused by removing the signaling entity (e.g., from a sample or from a nucleic acid probe, etc.), and / or chemically altering the signaling entity in some manner, for example, by photobleaching the signaling entity, bleaching the structure of the signaling entity, or chemically altering the structure of the signaling entity, such as by reduction, etc. For example, in one set of embodiments, the fluorescent signaling entity can be inactivated by chemical or optical techniques, such as oxidation, photobleaching, chemical bleaching, stringent washing or enzymatic digestion or reaction by exposure to an enzyme, dissociation of the signaling entity from other components (e.g., a probe), chemical reaction of the signaling entity (e.g., with a reactant that can alter the structure of the signaling entity), etc. For example, bleaching can occur by exposure to oxygen, a reducing agent, or the signaling entity can be chemically cleaved from a nucleic acid probe and washed away via fluid flow.

[0131] In some embodiments, various nucleic acid probes (including primary and / or secondary nucleic acid probes) may include one or more signaling entities. If more than one nucleic acid probe is used, the signaling entities may be the same or different from each other. In certain embodiments, the signaling entity is any entity capable of emitting light. For example, in one embodiment, the signaling entity is luminescent. In other embodiments, the signaling entity may be phosphorescent, radioactive, absorptive, etc. In some cases, the signaling entity is any entity that can be measured in a sample at a relatively high resolution (e.g., at a resolution better than the wavelength or diffraction limit of visible light). The signaling entity may be, for example, a dye, a small molecule, a peptide, or a protein, etc. In some cases, the signaling entity may be a single molecule. If multiple secondary nucleic acid probes are used, the nucleic acid probe may include the same or different signaling entities.

[0132] Non-limiting examples of signal transduction entities include fluorescent entities (fluorophores) or phosphorescent entities, such as cyanine dyes (e.g., Cy2, Cy3, Cy3B, Cy5, Cy5.5, Cy7, etc.), Alexa Fluor dyes, Atto dyes, photoswitchable dyes, photoactivated dyes, fluorescent dyes, metal nanoparticles, semiconductor nanoparticles or "quantum dots", fluorescent proteins, such as GFP (green fluorescent protein) or photoactivated fluorescent proteins (such as PAGFP, PSCFP, PSCFP2, Dendra, Dendra2, EosFP, tdEos, mEos2, mEos3, PamCherry, PAtagRFP, mMaple, mMaple2 and mMaple3). Other suitable signal transduction entities are known to those of ordinary skill in the art. See, for example, U.S. Patent No. 7,838,302 or WO 2015160690 A1, each of which is incorporated herein by reference in its entirety. In some cases, spectrally different fluorescent dyes can be used.

[0133] In one set of embodiments, the signaling entity can be attached to the oligonucleotide sequence via a bond that can be cleaved to release the signaling entity. In one set of embodiments, the fluorophore can be conjugated to the oligonucleotide via a cleavable bond (such as a photocleavable bond). Non-limiting examples of photocleavable bonds include, but are not limited to, 1-(2-nitrophenyl)ethyl, 2-nitrobenzyl, biotin phosphoramidite, acrylic acid phosphoramidite, diethylaminocoumarin, 1-(4,5-dimethoxy-2-nitrophenyl)ethyl, cyclododecyl(dimethoxy-2-nitrophenyl)ethyl, 4-aminomethyl-3-nitrobenzyl, (4-nitro-3-(1-chlorocarbonyloxyethyl)phenyl)methyl-S-acetylthioate, (4-nitro-3-(1-chlorocarbonyloxyethyl)phenyl)methyl-3-(2-pyridyldithiopropionic acid)ester, 3-(4,4'-dimethoxytrityl)-1-(2-nitrophenyl)-propane-1,3-diol -[2-cyanoethyl-(N,N-diisopropyl)]-phosphoramidite, 1-[2-nitro-5-(6-trifluoroacetylhexanamidomethyl)phenyl]-ethyl-[2-cyano-ethyl-(N,N-diisopropyl)]-phosphoramidite, 1-[2-nitro-5-(6-(4,4'-dimethoxytrityloxy)butyramidomethyl)phenyl]-ethyl-[2-cyanoethyl-(N,N-diisopropyl)]-phosphoramidite, 1-[2-nitro-5-(6-(N-(4,4'-dimethoxytrityl))-biotinamidohexanamido-methyl)phenyl]-ethyl-[2-cyanoethyl-(N,N-diisopropyl)]-phosphoramidite, or similar linkers. In another set of embodiments, the fluorophore can be conjugated to the oligonucleotide via a disulfide bond. Disulfide bonds can be cleaved by a variety of reducing agents, such as, but not limited to, dithiothreitol, dithioerythritol, β-mercaptoethanol, sodium borohydride, thioredoxin, glutaredoxin, trypsinogen, hydrazine, diisobutylaluminum hydride, oxalic acid, formic acid, ascorbic acid, phosphorous acid, tin chloride, glutathione, thioglycolate, 2,3-dimercaptopropanol, 2-mercaptoethylamine, 2-aminoethanol, tris(2-carboxyethyl)phosphine, bis(2-mercaptoethyl)sulfone, N,N'-dimethyl-N,N'-bis(mercaptoacetyl)hydrazine, 3-mercaptopropionate, dimethylformamide, thiopropyl agarose, tri-n-butylphosphine, cysteine, ferric sulfate, sodium sulfite, phosphites, hypophosphites, phosphorothioates, and the like, and / or any combination of these. In another embodiment, the fluorophore can be conjugated to the oligonucleotide via one or more phosphorothioate-modified nucleotides, wherein the sulfur modification replaces the bridging oxygen and / or the non-bridging oxygen. In certain embodiments, the fluorophore can be cleaved from the oligonucleotide via the addition of a compound such as, but not limited to, iodoethanol, iodine mixed in ethanol, silver nitrate, or mercuric chloride. In yet another set of embodiments, the signaling entity can be chemically inactivated by reduction or oxidation.For example, in one embodiment, sodium borohydride can be used to reduce a chromophore such as Cy5 or Cy7 to a stable non-fluorescent state. In still another set of embodiments, the fluorophore can be conjugated to an oligonucleotide via an azo bond, and the azo bond can be cleaved with 2-[(2-N-arylamino)phenylazo]pyridine. In yet another set of embodiments, the fluorophore can be conjugated to an oligonucleotide via a suitable nucleic acid segment, which can be cleaved after being suitably exposed to a DNA enzyme (e.g., exodeoxyribonuclease or endodeoxyribonuclease). Examples include, but are not limited to, deoxyribonuclease I or deoxyribonuclease II. In one set of embodiments, cleavage can occur via a restriction endonuclease. Non-limiting examples of potentially suitable restriction endonucleases include BamHI, BsrI, NotI, XmaI, PspAI, DpnI, MboI, MnlI, Eco57I, Ksp632I, DraIII, AhaII, SmaI, MluI, HpaI, ApaI, BclI, BstEII, TaqI, EcoRI, SacI, HindII, HaeII, DraII, Tsp509I, Sau3AI, PacI, etc. More than 3000 restriction enzymes have been studied in detail, and more than 600 of them are commercially available. In another set of embodiments, the fluorophore can be conjugated to biotin, and the oligonucleotide is conjugated to avidin or streptavidin. The interaction between biotin and avidin or streptavidin allows the fluorophore to be conjugated to the oligonucleotide, and when fully exposed to excessive addition, free biotin can "compete out" in the connection, thereby causing cutting to occur. In addition, in another set of embodiments, a corresponding "toe-hold-probe" can be used to remove the probe, which contains the same sequence as the probe and an additional number of bases (e.g., 1-20 additional bases, e.g., 5 additional bases) that have homology to the coding probe. These probes can be displaced from the labeled readout probe by strand displacement interactions.

[0134] As used herein, the term "light" generally refers to electromagnetic radiation having any suitable wavelength (or equivalently, frequency). For example, in some embodiments, light can include wavelengths in the optical or visual range (e.g., having a wavelength between about 400nm and about 700nm, i.e., "visible light"), infrared wavelengths (e.g., having a wavelength between about 300 microns and 700nm), ultraviolet wavelengths (e.g., having a wavelength between about 400nm and about 10nm), etc. In some cases, as discussed in detail below, more than one entity can be used, i.e., chemically (e.g., structurally) different or distinct entities. However, in other cases, the entities can be chemically identical or at least chemically substantially identical.

[0135] Another aspect of the present invention relates to a computer-implemented method. For example, a computer and / or automated system capable of automatically and / or repeatedly performing any method described herein may be provided. As used herein, an "automated" device refers to a device capable of operating without human guidance, that is, an automated device can perform a function during a period of time after anyone has completed any action taken to facilitate the function, for example, by inputting instructions into a computer to start a process. Typically, the automated equipment can perform repeated functions after this point in time. In some cases, the processing steps may also be recorded on a machine-readable medium.

[0136] For example, in some cases, a computer can be used to control the imaging of a sample, such as using fluorescence microscopy, STORM or other super-resolution techniques, such as those described herein. In some cases, a computer can also control operations such as drift correction, physical registration, hybridization and cluster alignment in image analysis, cluster decoding (e.g., fluorescence cluster decoding), error detection or correction (e.g., as discussed herein), noise reduction, identification of foreground features from background features (e.g., noise or debris in an image), etc. As an example, a computer can be used to control the activation and / or excitation of a signaling entity within a sample, and / or the acquisition of an image of a signaling entity. In one set of embodiments, a sample can be excited using light having various wavelengths and / or intensities, and a computer can be used to associate the wavelength sequence of light used to excite the sample with an image of a sample containing a signaling entity acquired. For example, a computer can apply light having various wavelengths and / or intensities to a sample to produce a different average number of signaling entities in each region of interest (e.g., one activated entity per position, two activated entities per position, etc.). In some cases, this information can be used to construct an image and / or determine (in some cases, as described above with high resolution) the location of the signaling entity. VI. Kit

[0137] The present disclosure provides a kit for performing the methods described herein. A kit for preparing FFPE tissue section samples and measuring nucleic acid targets in samples is provided. In embodiments, the kit comprises anchor probes and anchoring agents disclosed herein and one or more other components. In embodiments, the kit also comprises a labeling agent disclosed herein for identifying cell types or tissue morphology. In some embodiments, the kit comprises many different labeling agents indicating tissues obtained from a specific disease (e.g., solid tumor cancer). In some embodiments, the kit also comprises a set of nucleic acid probes (e.g., MERFISH probes described herein) and one or more other components for MERFISH imaging.

[0138] The one or more other kit components may include one or more buffers; nuclear counterstains; total RNA content counterstains; imaging buffers; software; and other components. The kit may also include instructions for using the kit components and for using any other reagents not included in the kit. The instructions may include variations that may be implemented.

[0139] In certain embodiments, kit components and protocols for preparing FFPE tissue section samples for transcriptome analysis are provided herein. In one embodiment, the kit comprises one or more of the following components: deparaffinization buffer, cross-linking solution buffer, conditioning buffer, sample preparation wash buffer, formamide wash buffer, gel embedding premix, cleaning premix, gel cover glass, pre-anchoring activator, anchoring buffer and digestion premix. Anchor probes for fixing target nucleic acids (e.g., RNA transcripts) and target probes and reagents thereof for specifically detecting target nucleic acids in prepared samples can also be provided. In an embodiment, a kit comprising at least a first anchor and a second anchor or anchor probe is provided.

[0140] Exemplary kit components are described in Example 1. Specific implementation plan

[0141] The following embodiments are provided according to the methods described herein.

[0142] Embodiment 1 is a method for detecting a nucleic acid target in a tissue sample, the method comprising: a. contacting a tissue sample containing a nucleic acid target with an anchor probe that specifically binds to the nucleic acid target; b. fixing the nucleic acid target-bound anchor probe in at least a portion of the tissue sample within a gel; c. cleaning up the tissue sample within the polymer gel by removing or degrading non-targets; d. contacting the tissue sample with a plurality of nucleic acid probes capable of selectively binding to the nucleic acid target; e. Detecting the nucleic acid probe bound to the nucleic acid target within the tissue sample.

[0143] Embodiment 2 is a method for detecting a nucleic acid target in a tissue sample, the method comprising: a. contacting a tissue sample containing a nucleic acid target with an anchoring agent, the anchoring agent comprising a first chemical portion that can react with and / or modify an internal base of the nucleic acid target and a second chemical portion that can be incorporated into the polymer gel; b. fixing the nucleic acid target-bound anchor in at least a portion of the tissue sample within a gel; c. cleaning up the tissue sample within the polymer gel by removing or degrading non-targets; d. contacting the tissue sample with a plurality of nucleic acid probes capable of selectively binding to the nucleic acid target; e. Detecting the nucleic acid probe bound to the nucleic acid target within the tissue sample.

[0144] Embodiment 3 is a method for detecting a nucleic acid target in a tissue sample, the method comprising: a. contacting a tissue sample containing a nucleic acid target with an anchoring agent, the anchoring agent comprising a first chemical portion that can react with and / or modify an internal base of the nucleic acid target and a second chemical portion that can be incorporated into the polymer gel; b. contacting the tissue sample with an anchor probe that specifically binds to the nucleic acid target; c. fixing the nucleic acid target-bound anchor probe or the nucleic acid target-bound anchor agent in at least a portion of the tissue sample within a gel; d. cleaning the tissue sample within the polymer gel by removing or degrading non-targets; e. contacting the tissue sample with a plurality of nucleic acid probes capable of selectively binding to the nucleic acid target; f. Detecting the nucleic acid probe bound to the nucleic acid target within the tissue sample.

[0145] Embodiment 4 is a method according to any one of embodiments 1-3, further comprising generating a codeword or barcode based on the distribution of the bound nucleic acid probes within the sample.

[0146] Embodiment 5 is a method according to embodiment 4, the method further comprising: for at least some of the codewords, matching the codewords with valid codewords in a codebook, optionally wherein if no match is found, applying error correction to the codeword to form a valid codeword or discarding the codeword.

[0147] Embodiment 6 is a method according to any one of embodiments 1, 2, 4 and 5, wherein step (c) of cleaning is performed after steps (a) and (b).

[0148] Embodiment 7 is a method according to any one of embodiments 3-6, wherein step (d) of cleaning is performed after steps (a)-(c).

[0149] Embodiment 8 is a method according to any one of embodiments 1-7, wherein the steps are performed in the described order.

[0150] Embodiment 9 is a method according to any one of embodiments 1-8, wherein the tissue sample is a formalin-fixed paraffin-embedded (FFPE) tissue section.

[0151] Embodiment 10 is a method according to any one of embodiments 1-8, wherein the tissue sample is deparaffinized and rehydrated prior to step (a).

[0152] Embodiment 11 is a method according to any one of embodiments 1-10, further comprising deparaffinizing and rehydrating the tissue sample prior to step (a).

[0153] Embodiment 12 is a method according to any one of embodiments 1-8, wherein the tissue sample is a fresh frozen tissue sample.

[0154] Embodiment 13 is a method according to any one of embodiments 1-8, wherein the tissue sample is a fixed frozen tissue sample.

[0155] Embodiment 14 is a method according to any one of embodiments 1-13, wherein the nucleic acid target is RNA.

[0156] Embodiment 15 is a method according to any one of embodiments 1-13, wherein the nucleic acid target is DNA.

[0157] Embodiment 16 is a method according to any one of embodiments 1-15, wherein the gel comprises polyacrylamide.

[0158] Embodiment 17 is a method according to any one of embodiments 1-16, wherein at least some of the anchor probes comprise poly dT moieties.

[0159] Embodiment 18 is a method according to embodiment 17, wherein at least some of the anchor probes comprise alternating dT and lock dT portions.

[0160] Embodiment 19 is a method according to any one of embodiments 16-18, wherein at least some of the anchor probes comprise an acrydite moiety capable of polymerizing with the gel.

[0161] Embodiment 20 is a method according to embodiment 19, wherein the acrydite moiety is bound to the 5' end of the anchor probe.

[0162] Embodiment 21 is a method according to embodiment 19, wherein the acrydite moiety is bound to the 3' end of the anchor probe.

[0163] Embodiment 22 is a method according to embodiment 19, wherein the acrydite moiety is bound to an internal base of the anchor probe.

[0164] Embodiment 23 is a method according to any one of embodiments 1 and 3-22, further comprising, before step (a), contacting the sample with an anchoring agent, wherein the anchoring agent comprises a first chemical part that can react with and / or modify the internal base of the nucleic acid target and a second chemical part that can be incorporated into the polymer gel.

[0165] Embodiment 24 is a method according to embodiment 23, wherein the fixing step (b) further comprises polymerizing a gel within the tissue sample, wherein the second chemical portion of the anchoring agent copolymerizes with the polymer gel.

[0166] Embodiment 25 is a method according to embodiment 23 or 24, wherein the second chemical moiety of at least some of the anchoring agents comprises an acrydite moiety capable of polymerizing with the gel.

[0167] Embodiment 26 is a method according to any one of embodiments 23-25, wherein at least some of the nucleic acid targets are immobilized within the gel via both the anchor probes and the anchoring agents that bind to the nucleic acid targets.

[0168] Embodiment 27 is a method according to any one of embodiments 1-26, wherein the non-target comprises a protein, a lipid, a DNA, an RNA, or an extracellular matrix.

[0169] Embodiment 28 is a method according to any one of embodiments 1-27, wherein clearing the tissue sample comprises removing or degrading proteins from the sample.

[0170] Embodiment 29 is a method according to any one of embodiments 1-28, wherein clearing the tissue sample comprises removing or degrading lipids from the sample.

[0171] Embodiment 30 is a method according to any one of embodiments 1-29, wherein cleaning up the tissue sample comprises removing or degrading non-target DNA from the sample.

[0172] Embodiment 31 is a method according to any one of embodiments 1-30, wherein clearing the tissue sample comprises removing or degrading extracellular matrix from the sample.

[0173] Embodiment 32 is a method according to any one of embodiments 1-31, wherein clearing the tissue sample comprises exposing the sample to an enzyme capable of degrading proteins.

[0174] Embodiment 33 is a method according to any one of embodiments 1-32, wherein clearing the tissue sample comprises exposing the sample to an enzyme capable of degrading DNA.

[0175] Embodiment 34 is a method according to any one of embodiments 1-33, wherein clearing the tissue sample comprises exposing the sample to an enzyme capable of degrading RNA.

[0176] Embodiment 35 is a method according to any one of embodiments 1-34, wherein clearing the tissue sample comprises exposing the sample to an enzyme capable of degrading a sugar or a sugar-modified biomolecule.

[0177] Embodiment 36 is a method according to any one of embodiments 1-35, wherein clearing the tissue sample comprises exposing the sample to a detergent.

[0178] Embodiment 37 is a method according to any one of embodiments 1-36, wherein clearing the tissue sample comprises exposing the gel to a protease.

[0179] Embodiment 38 is a method according to embodiment 37, wherein the protease comprises proteinase K.

[0180] Embodiment 39 is a method according to any one of embodiments 1-38, wherein clearing the tissue sample comprises exposing the gel to guanidine hydrochloride.

[0181] Embodiment 40 is a method according to any one of embodiments 1-39, wherein clearing the tissue sample comprises exposing the gel to Triton X-100 (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether).

[0182] Embodiment 41 is a method according to any one of embodiments 1-40, wherein clearing the tissue sample comprises exposing the gel to sodium dodecyl sulfate.

[0183] Embodiment 42 is a method according to any one of embodiments 1-41, wherein clearing the tissue sample comprises exposing the gel to ethylenediaminetetraacetic acid.

[0184] Embodiment 43 is a method according to any one of embodiments 1-42, wherein the plurality of nucleic acid probes comprises smFISH probes.

[0185] Embodiment 44 is a method according to any one of embodiments 1-43, wherein the plurality of nucleic acid probes comprises MERFISH probes.

[0186] Embodiment 45 is a method according to any one of embodiments 1-44, wherein step (d) further comprises amplification of the nucleic acid probe.

[0187] Embodiment 46 is a method according to any one of embodiments 1-45, wherein the detecting comprises imaging using optical microscopy.

[0188] Embodiment 47 is a method according to any one of embodiments 1-46, wherein the detecting comprises imaging using fluorescence microscopy.

[0189] Embodiment 48 is a method according to embodiment 47, wherein the method includes imaging using epifluorescence microscopy, total internal reflection microscopy, highly inclined thin illumination (HILO) microscopy, light sheet microscopy, scanning confocal microscopy, scanning line confocal microscopy, spinning disk confocal microscopy or other comparable conventional microscopy techniques.

[0190] Embodiment 49 is a method according to embodiment 47, wherein the method includes using multiplexed fluorescent in situ hybridization for imaging.

[0191] Embodiment 50 is a method according to embodiment 47, wherein the method comprises using multiplexed error robust fluorescent in situ hybridization (MERFISH) for imaging.

[0192] Embodiment 51 is a method according to any one of embodiments 47-50, wherein the method comprises using multiple rounds of fluorescent in situ hybridization for imaging.

[0193] Embodiment 52 is a method according to any one of embodiments 1-51, wherein the nucleic acid probe comprises a targeting sequence and one or more reading sequences.

[0194] Embodiment 53 is a method according to embodiment 52, the method further comprising determining the read sequence based on determining the binding of the read sequence to the target nucleic acid target.

[0195] Embodiment 54 is a method according to embodiment 53, wherein the codeword or barcode is generated based on the determination of the read sequence within the gel.

[0196] Embodiment 55 is a method according to any one of embodiments 52-54, wherein the read sequence is taken from a set of orthogonal sequences, and the orthogonal sequences have less than 15 base pairs of homology with each other and with the nucleic acid species in the sample.

[0197] Embodiment 56 is a method according to any one of embodiments 4-55, wherein each of the codewords represents one of the multiple different nucleic acid targets and comprises multiple binary values ​​1 and 0, wherein a value of 1 is obtained when a signal is detected at the corresponding position within the sample, and a value of 0 is obtained when no signal is detected.

[0198] Embodiment 57 is a method according to any one of embodiments 4-56, wherein the codewords representing the multiple different nucleic acid targets at the positions within the sample are generated, wherein each of the codewords represents one of the multiple different nucleic acid targets and comprises multiple binary values ​​1 and 0, wherein the value 1 is obtained when a signal is detected from one of the multiple read probe hybridized complexes or one of the different multiple read probe hybridized complexes at the corresponding position within the sample, and the value 0 is obtained when no signal is detected from one of the multiple read probe hybridized complexes or one of the different multiple read probe hybridized complexes at the corresponding position within the sample.

[0199] Embodiment 58 is a method according to any one of embodiments 5-57, wherein the codebook comprises valid codewords for the plurality of nucleic acid targets.

[0200] Embodiment 59 is a method according to any one of embodiments 5-58, wherein the step (h) of matching the codeword with a valid codeword in a codebook includes comparing the codeword with the valid codewords in the codebook, and if the codeword does not match one of the valid codewords in the codebook, applying an error detection or correction system, matching the codeword with another of the valid codewords in the codebook, or discarding the codeword, wherein the codebook contains valid codewords for the multiple nucleic acid targets.

[0201] Embodiment 60 is a method according to any one of embodiments 1-59, wherein prior to step (a), the tissue sample is contacted with at least one labeling agent for labeling at least one cellular component.

[0202] Embodiment 61 is a method according to any one of embodiments 1-60, further comprising, before step (a), contacting the tissue sample with at least one labeling agent for labeling at least one cellular component before step (a).

[0203] Embodiment 62 is a method according to embodiment 60 or 61, wherein the at least one labeling agent comprises at least three oligonucleotide-conjugated labeling probes, each probe comprising an oligonucleotide conjugated to an anchoring portion that can be attached to a gel and (2) a binding portion that can bind to a cellular component, wherein the binding portion comprises (i) a protein binding portion that can bind to a cellular protein component; (ii) a carbohydrate binding portion that can bind to a cellular carbohydrate component; or (iii) a chemical binding portion that can bind to or be incorporated into a cellular component.

[0204] In some preferred embodiments, the present disclosure provides a method for anchoring a target nucleic acid within a matrix and clearing non-target cellular components, the method comprising: contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises an oligonucleotide that hybridizes with the target nucleic acid; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; and clearing the non-target cellular components from the polymer matrix, wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix-anchored target nucleic acid sample. In some preferred embodiments, the first anchoring agent is an alkylating agent. In some preferred embodiments, the alkylating agent is selected from altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, nitrogen mustard, melphalan, oxaliplatin, temozolomide, thiotepa and trabectedin. In some preferred embodiments, the second anchoring agent comprises alternating dT and lock dT portions that hybridize with the target nucleic acid. In some preferred embodiments, the second anchoring agent comprises a poly dT portion that hybridizes with the target nucleic acid. In some preferred embodiments, the first anchoring agent and the second anchoring agent each comprise an acrydite portion that is covalently bound to the polymer matrix. In some preferred embodiments, the first anchoring agent is an alkylating agent derivatized with an acrydite portion. In some preferred embodiments, the second anchoring agent comprises a poly dT portion that hybridizes with the target nucleic acid and an acrydite portion that is covalently bound to the polymer matrix. In some preferred embodiments, the target nucleic acid is RNA. In some preferred embodiments, the target nucleic acid is DNA. In some preferred embodiments, the method further comprises contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes hybridized with the target nucleic acid. In some preferred embodiments, the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robust fluorescent in situ hybridization (MERFISH) probe. In some preferred embodiments, the one or more primary oligonucleotide probes comprise a first portion containing a target sequence and a second portion containing one or more read sequences. In some preferred embodiments, the method further comprises determining the read sequence based on: contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising a recognition sequence hybridized with the read sequence of the primary nucleic acid probe. In some preferred embodiments, the method further comprises imaging using multiplexed fluorescent in situ hybridization, which comprises contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes hybridized with the target nucleic acid, and comprises one or more consecutive steps of adding a plurality of secondary nucleic acid probes comprising a labeling portion.In some preferred embodiments, the method further comprises imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, which comprises contacting the anchored target nucleic acid sample with one or more MERFISH probes hybridized to the target nucleic acid. In some preferred embodiments, the method comprises imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally different fluorescent label, are used to read out multiple readout sequences simultaneously.

[0205] In some preferred embodiments, the present disclosure provides a method for anchoring a target RNA within a matrix and clearing non-target cellular components, the method comprising: contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent comprises an alkylating agent that forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises a poly-T sequence that is complementary to and hybridizes to the target RNA, and wherein the first anchoring agent and the second anchoring agent each comprise an acrydite portion that is covalently bound to the matrix; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; and clearing the non-target cellular components from the polymer matrix, wherein the target RNA remains anchored in the polymer matrix to form a matrix-anchored target RNA sample. In some preferred embodiments, the alkylating agent is selected from altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, nitrogen mustard, melphalan, oxaliplatin, temozolomide, thiotepa and trabectedin. In some preferred embodiments, the second anchoring agent comprises alternating dT and lock dT parts hybridized with the target RNA. In some preferred embodiments, the method further comprises contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes hybridized with the target nucleic acid. In some preferred embodiments, the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robustness fluorescent in situ hybridization (MERFISH) probe. In some preferred embodiments, the one or more primary oligonucleotide probes comprise a first portion containing a target sequence and a second portion containing one or more read sequences. In some preferred embodiments, the method further comprises determining the read sequence based on: contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising a recognition sequence that hybridizes to the read sequence of the primary nucleic acid probe. In some preferred embodiments, the method further comprises imaging using multiplexed fluorescent in situ hybridization, which comprises contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes that hybridize to the target nucleic acid, and comprising one or more consecutive steps of adding a plurality of secondary nucleic acid probes comprising a labeling portion. In some preferred embodiments, the method further comprises imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, which comprises contacting the anchored target nucleic acid sample with one or more MERFISH probes that hybridize to the target nucleic acid. In some preferred embodiments, the method further comprises imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally different fluorescent marker, are used to simultaneously read out multiple read sequences.

[0206] In some preferred embodiments, the present disclosure provides a method for imaging a target nucleic acid within a matrix and clearing non-target cellular components, the method comprising: contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid and the second anchoring agent comprises an oligonucleotide that hybridizes with the target nucleic acid; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; clearing the non-target cellular components from the polymer matrix, wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix-anchored target nucleic acid sample; and contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes, the one or more primary oligonucleotide probes hybridizing with the target nucleic acid and a plurality of secondary nucleic acid probes, the secondary nucleic acid probes comprising a fluorescent label and a recognition sequence that hybridizes with the sequence of the primary nucleic acid probes, and imaging the target nucleic acid. In some preferred embodiments, the first anchoring agent is an alkylating agent. In some preferred embodiments, the alkylating agent is selected from altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, nitrogen mustard, melphalan, oxaliplatin, temozolomide, thiotepa and trabectedin. In some preferred embodiments, the second anchoring agent comprises alternating dT and lock dT portions that hybridize with the target nucleic acid. In some preferred embodiments, the second anchoring agent comprises a poly dT portion that hybridizes with the target nucleic acid. In some preferred embodiments, the first anchoring agent and the second anchoring agent each comprise an acrydite portion that is covalently bound to the polymer matrix. In some preferred embodiments, the first anchoring agent is an alkylating agent derivatized with an acrydite portion. In some preferred embodiments, the second anchoring agent comprises a poly dT portion that hybridizes with the target nucleic acid and an acrydite portion that is covalently bound to the polymer matrix. In some preferred embodiments, the target nucleic acid is RNA. In some preferred embodiments, the target nucleic acid is DNA. In some preferred embodiments, the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robustness fluorescence in situ hybridization (MERFISH) probe. In some preferred embodiments, the one or more primary oligonucleotide probes comprise a first portion containing a target sequence and a second portion containing one or more read sequences. In some preferred embodiments, the method further comprises determining the read sequence based on: contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising a recognition sequence hybridized with the read sequence of the primary nucleic acid probe. In some preferred embodiments, the secondary nucleic acid probe is added in one or more consecutive steps and imaging is performed between each consecutive round of adding the secondary nucleic acid probe.In some preferred embodiments, the method further comprises imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, which comprises contacting the anchored target nucleic acid sample with one or more MERFISH probes hybridized to the target nucleic acid. In some preferred embodiments, the method further comprises imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally different fluorescent label, are used to read out multiple readout sequences simultaneously.

[0207] In some preferred embodiments, the present disclosure provides a method for imaging a target RNA within a matrix and clearing non-target cellular components, the method comprising: contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent comprises an alkylating agent that forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises a poly-T sequence that is complementary to and hybridizes to the target RNA, and wherein the first anchoring agent and the second anchoring agent each comprise an acrydite portion that is covalently bound to the matrix; embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; clearing the non-target cellular components from the polymer matrix, wherein the target RNA remains anchored in the polymer matrix to form a matrix-anchored target RNA sample; and, contacting the anchored target RNA sample with one or more primary oligonucleotide probes that hybridize with the target RNA and a plurality of secondary nucleic acid probes that comprise a fluorescent label and a recognition sequence that hybridizes with the sequence of the primary nucleic acid probes, and imaging the target nucleic acid. In some preferred embodiments, the alkylating agent is selected from altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, nitrogen mustard, melphalan, oxaliplatin, temozolomide, thiotepa and trabectedin. In some preferred embodiments, the second anchoring agent comprises alternating dT and lock dT parts that hybridize with the target nucleic acid. In some preferred embodiments, the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robustness fluorescent in situ hybridization (MERFISH) probe. In some preferred embodiments, the one or more primary oligonucleotide probes comprise a first portion containing a target sequence and a second portion containing one or more read sequences. In some preferred embodiments, the method further comprises determining the read sequence based on: contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising a recognition sequence that hybridizes with the read sequence of the primary nucleic acid probe. In some preferred embodiments, the secondary nucleic acid probe is added in one or more consecutive steps and imaging is performed between each consecutive round of adding the secondary nucleic acid probe. In some preferred embodiments, the method further comprises imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, which comprises contacting the anchored target nucleic acid sample with one or more MERFISH probes hybridized to the target nucleic acid. In some preferred embodiments, the method further comprises imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally different fluorescent label, are used to read multiple readout sequences simultaneously.

[0208] Although embodiments of the present invention have been explained in detail, it should be understood that other embodiments can be envisioned. Therefore, it is not intended that the scope of the present invention be limited to the details of the construction and arrangement of the components set forth in the following description or shown in the accompanying drawings. The present invention can have other embodiments and can be practiced or executed in various ways. In addition, when describing an embodiment, for the sake of clarity, specific terms will be adopted.

[0209] It must also be noted that, as used in the specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to "a probe" is intended to also include a plurality of probes, and reference to "a target" is intended to also include a plurality of targets, etc.

[0210] Unless the context clearly requires otherwise, the term "or" is used herein in an inclusive sense, ie, equivalent to "and / or".

[0211] Numerical ranges include the numbers that define the range. Taking into account significant figures and errors associated with measurement, measured values ​​and measurable values ​​should be understood as approximate values. Therefore, unless otherwise indicated, the numerical parameters set forth in the following description and the attached claims are approximate values ​​that can vary depending on the desired properties sought to be obtained. At least and without attempting to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be interpreted as being based on the number of reported significant figures and by applying ordinary rounding techniques.

[0212] The term "about" or "approximately" means an acceptable error for a particular value as determined by one of ordinary skill in the art, the error depending in part on how the value is measured or determined; or a degree of variation that does not substantially affect the characteristics of the subject matter being described.

[0213] The use of "comprise," "comprises," "comprising," "contain," and "contains" are not intended to be limiting and mean that at least the named compound, element, particle, or method step is present in the composition or article or method, but does not exclude the presence of other compounds, materials, particles, method steps, even if other such compounds, materials, particles, method steps have the same function as those named.

[0214] In addition, when describing the embodiments, for the sake of clarity, terminology will be employed. For each term, it is intended to consider the broadest meaning as understood by those skilled in the art, and each term includes all technical equivalents that operate in a similar manner to achieve a similar purpose.

[0215] It should also be understood that the reference to one or more method steps does not exclude the presence of additional method steps or intermediate method steps between those steps that are explicitly identified. Similarly, it should also be understood that the reference to one or more components in a structure (fabric) or system does not exclude the presence of additional components or intermediate components between those components that are explicitly identified.

[0216] Those skilled in the art will appreciate that the above drawings and the following examples are for illustration purposes only, and neither the drawings nor the examples are intended to limit the scope of the disclosed teachings in any way. VII. Examples

[0217] The following examples are provided to illustrate certain disclosed embodiments and should not be construed as limiting the scope of the disclosure in any way. Example 1. In situ single-cell transcriptomic imaging in FFPE samples by MERFISH (“Protocol A”)

[0218] This example illustrates a sample protocol ("Protocol A") for preparing FFPE samples for MERFISH imaging. It should be understood that Protocol A can be used with any downstream in situ imaging, not just with MERFISH imaging, and for anchoring fragmented RNA, and that this example is provided for illustrative purposes only and does not imply any limitation on the methods described herein. Protocol A and a comparative protocol ("Protocol B") (in the comparative protocol, MERFISH and one or more anchoring agents are added to the sample prior to cleaning FFPE and fresh frozen samples) are shown in Figure 1 middle.

[0219] In certain embodiments, Scheme A can be performed as follows: 1) Fiducial coating on a glass slide (e.g., MERSCOPE slide, Vizgen, #20400001) to enable image registration for multiple rounds of imaging: a. Prepare a bead solution (e.g., Spherotech fluorescent beads, catalog number: FP-0252-2) at a 1:500 dilution in PBS. b. Add 500 μl of bead solution to the center of the bead pre-coated coverslip to cover approximately 80% of the entire area of ​​the coverslip. Avoid the bead solution from flowing under the coverslip. Incubate at room temperature for 10 minutes. c. Aspirate the bead solution. d. Wash once with 500 μl PBS and aspirate PBS. Avoid the bead solution flowing under the coverslip. e. Add another 500 μl of PBS to the center of the coverslip. 2) Slice FFPE slices onto reference coated coverslips a. Immediately before sectioning the FFPE slices, aspirate the PBS solution. b. Place one or more FFPE slices of 4-5 μm thickness on the prepared coverslip. c. Allow the coverslip to dry at room temperature for 2-3 minutes. d. Dry the coverslip in an oven at 50°C-55°C for 10 minutes. e. Completely remove any remaining water droplets. f. FFPE coverslips can be used immediately or stored in a -20°C freezer for 1-2 months. 3) Deparaffinization and rehydration of FFPE sections a. Add 400 μl of deparaffinized solution (e.g., Zymo Research, D3067-1-20) to the center of the coverslip. Allow the solution to gradually cover the entire coverslip. b. Place the coverslip in an oven at 50-55 degrees for 5 minutes. c. Aspirate the solution. d. Add another 350ul of deparaffinized solution to the center of the coverslip, so that the solution covers the entire coverslip. e. Incubate at room temperature for 2 minutes. f. Aspirate the solution. g. Add 5 ml of 100% ethanol to the culture dish with the coverslip to rinse, and aspirate. h. Add 5 ml of 100% ethanol to the dish with the coverslip and incubate at room temperature for 2 minutes and aspirate. i. Repeat step 3(h) again. j. Add 5 ml of 90% ethanol to the culture dish with the coverslip and incubate at room temperature for 5 minutes and aspirate. k. Add 5 ml of 70% ethanol to the culture dish with the coverslip and incubate at room temperature for 5 minutes and aspirate. l. Coverslips can be stored in 70% ethanol for up to one month. 4) Antigen retrieval of FFPE sections a. Add 5 ml of citrate-based antigen retrieval buffer to rinse and aspirate. b. Add 5 ml of citrate-based antigen retrieval buffer. Place the dish in an oven at 90-95 degrees for 15 minutes. c. Place the dish on the bench at room temperature for 5 minutes and aspirate. 5) Immunostaining of protein biomarkers for cell segmentation and protein imaging. In this step, cell morphology and protein staining are performed. a. Add 5 ml PBS to the dish to rinse, and aspirate. b. Add 100 μl of blocking solution containing 3% bovine serum albumin (BSA) to cover the entire tissue. Incubate at room temperature for 45-60 minutes. Aspirate. c. Add 100 μl of blocking solution containing 3% BSA + primary antibody for cell boundary 3 or other antibodies at a dilution according to a predetermined concentration. The solution needs to cover the entire tissue. Incubate at room temperature for 60 minutes. d. Add 5 ml of PBS to the dish. Incubate on the bench for 5 minutes. Agitate occasionally and aspirate. e. Repeat step 5(d) once. f. Add 100 μl of blocking solution containing 3% BSA + secondary antibody for cell border / cell morphology staining according to the predetermined concentration. Incubate at room temperature for 60 minutes. g. Add 5 ml of PBS to the dish. Incubate on the bench for 5 minutes. Agitate occasionally and aspirate. h. Repeat step 5(g) twice. 6) Anchoring pretreatment of FFPE slices to prepare the tissue for anchoring. In this step, the first anchoring agent is added to the sample and forms a covalent bond with the nucleic acid. a. Add 4 ml of Anchor Pretreatment Dilution Buffer to the dish to rinse and aspirate. b. Add 4 ml of anchor pretreatment dilution buffer to the dish. Incubate in a 37°C incubator for 30 minutes and aspirate. c. Add 100 μl of anchoring pretreatment solution on the tissue to cover the entire tissue. Incubate in a 37°C incubator for 2 hours. 7) Anchoring RNA molecules with poly-T probes. In this step, a second anchoring agent or anchoring probe is added to the sample and hybridizes with the poly-A tail of the mRNA present in the sample. a. Add 5 ml of Sample Preparation Wash Buffer to the dish to rinse, and aspirate. b. Add 5 ml of formamide wash buffer to the dish. Incubate in a 37°C incubator for 30 minutes. Aspirate the solution. c. Add 75 μl of Poly-T anchoring buffer to the center of the tissue. Use a 2X2 cm piece of parafilm to spread over and cover the entire tissue. Incubate overnight (at least >16 hours) in a 37 degree incubator. d. Add 5 ml of formamide wash buffer to the dish, incubate in a 47°C incubator for 15 minutes, and aspirate. 8) Gel embedding and tissue cleaning to remove autofluorescence background. In this step, when the first anchor and the second anchor each form a covalent bond with the polyacrylamide gel, the mRNA is fixed in the gel, and the unfixed cell components are removed, thereby providing a gel-fixed target nucleic acid sample. a. Add 5 ml of Sample Preparation Wash Buffer to the dish to rinse. Aspirate. b. Clean the gel coverslips (Vizgen, Inc) by spraying with RNaseZap solution and wiping with a Kimwipe, then spraying with 70% ethanol and wiping with a Kimwipe. c. Add 50 μL of Gel Slick Solution (VWR, catalog number 12001-812) to the gel coverslip and wipe gently with a Kimwipe to spread the Gel Slick. d. Prepare a gel embedding solution comprising polyacrylamide, 0% w / v ammonium persulfate solution and N,N,N',N'-tetramethylethylenediamine. e. Aspirate the sample to prepare the wash buffer. Keep 100 μL of gel embedding solution in the vial. Add the remaining 5 mL of embedding solution and incubate at room temperature for 1 min. f. Using a pipette, transfer most of the embedding solution to waste (to monitor gel formation). g. Aspirate to dry the slide, leaving enough liquid to cover the tissue section. h. Add 50 μL of the reserved gel embedding solution onto the tissue section. i. Place the tips of a pair of tweezers over an area of ​​the MERSCOPE slide without touching the tissue section. Use the tweezers to pick up a 20 mm Gel Slick treated gel coverslip. With the Gel Slick treated side facing down toward the tissue, place the edge of the gel coverslip against the tips of the tweezers resting on the MERSCOPE slide to create stability and slowly lower the gel coverslip onto the tissue section to spread the gel embedding solution. If necessary, adjust the gel coverslip so that it is centered on the MERSCOPE slide. Gently press on the gel coverslip to squeeze out excess gel embedding solution and remove excess gel embedding solution by aspiration. j. Incubate at room temperature for 1.5 h. k. Make sure to wear eye protection during this step. Gently lift the 20 mm GelSlick treated gel coverslip with the sharp tip of the Hobby Blade and discard the gel coverslip appropriately. 1. Warm the cleanup premix (containing SDS, 2xSSC and Trition-x 100) at 37°C for 30 min before use. The cleanup premix should be a clear solution before use. If the solution is turbid, warm until the solution becomes clear. Prepare a clearing solution containing the cleanup premix and proteinase K (100:1 volume ratio). m. (Optional) For resistant tissues, add 200 μl of digestion premix containing 200 μl of a mixture of enzymes that can digest connective tissue + 10 μl of RNase inhibitor to the gel. Incubate in a 37 degree incubator for 1-6 hours. n. Add 5 ml of clearing solution to the dish. Seal the dish with a piece of parafilm. Incubate in a 47 degree incubator for 18-24 hours. After 18 hours of incubation, monitor tissue clarity. If the tissue becomes clear, proceed to the next step. o. Photobleach for 3-4 hours. (Note: This photobleaching step can be performed after "Step 3)" above) p. Samples can be stored in 5 ml of clearing solution in a 37 degree incubator for up to 1 week. 9) Hybridization with MERFISH encoding probes ("primary oligonucleotide probes") for imaging the anchored mRNA, and the probes are designed to hybridize to multiple target nucleic acids within the anchored mRNA. a. Add 5 ml of sample preparation wash buffer. Shake on a shaker at room temperature for 5 minutes and aspirate. b. Repeat step 9(a) three times. c. Add 5 ml of formamide wash buffer to the dish. Incubate in a 37°C incubator for 30 minutes. Aspirate the solution. d. Add 80 μl of MERFISH encoding probe ("primary oligonucleotide probe") to the gel with anchored mRNA. Use a 2X2 cm piece of parafilm to spread over and cover the entire tissue. Incubate in a 37 degree incubator for two days (36-48 hours). 10) Washing to remove excess or unbound primary oligonucleotide probe: a. Add 5 ml of formamide wash buffer to the dish. Incubate in a 47°C incubator for 30 minutes and aspirate. b. Repeat 10(a) once. c. Samples can be stored in 5 ml of clean-up solution in a 37 degree incubator for up to 1 week. After storage, samples need to be washed with 5 ml of sample preparation wash buffer. Shake on a shaker at room temperature for 5 minutes and aspirate. Repeat the wash once with 5 ml of sample preparation wash buffer. 11) (Optional) Signal Enhancement (Amplification) a. Add 100ul of enhancer solution to the gel along with the tissue. Incubate overnight (>16 hours) in a 37 degree incubator. b. Add 5 ml of Formamide Wash Buffer to the dish and incubate on the benchtop at room temperature for 5 minutes. c. Add 5 ml of Formamide Wash Buffer to the dish and incubate on the benchtop at room temperature for 10 minutes. d. Rinse with 5 ml of sample preparation wash buffer. 12) Data acquisition and analysis a. Add 3 mL of DAPI and poly-T staining reagent and incubate on a shaker for 15 min. b. Wash with 5 mL of formamide wash buffer and incubate for 10 min. c. Wash with 5 mL of sample preparation wash buffer. d. The sample coverslip was placed on MERSCOPE (Vizgen, Inc.) and secondary nucleic acid probes ("readout probes") were added sequentially to acquire data and then analyzed. Example 2. In situ single-cell transcriptomic imaging in FFPE samples by MERFISH

[0220] This example illustrates the results of MERFISH imaging in FFPE samples after target fixation and cleanup methods according to the present disclosure. After fixing the target nucleic acid and cleaning up non-target cell components, a primary nucleic acid probe is added, which is designed to hybridize with the fixed target nucleic acid, and then a readout probe that binds to the complementary sequence ("reading sequence") of the primary nucleic acid probe and contains a fluorescent label is added. Further details of the method are provided in Example 1 above.

[0221] Figure 2A-2C Shown is MERFISH imaging using a 128-plex gene detection panel in FFPE mouse small intestine. Figure 2A The spatial distribution of selected genes in tissues is shown. Figure 2B Shown are the tissue morphology visualized by selected transcripts (left) and the distribution of all transcripts in the magnified area.

[0222] To determine the accuracy of these measurements, the copy number of each gene as determined by MERFISH was compared for tissue sections. Figure 2C The "MERFISH counts", "MERFISH" in Figure 5 were compared with the abundance determined by RNA-seq (as measured in FPKM derived from the same tissue sample). Figure 2C As shown, MERFISH counts were strongly correlated with bulk RNA sequencing FPKM data (r = 0.81), indicating that the measurements were quantitative and highly accurate.

[0223] Similarly, Figure 3 shows MERFISH imaging using a 244-plex gene panel in FFPE human colon cancer. Figure 3A The spatial distribution of selected genes in tissues is shown. Figure 3B Shown are the tissue morphology visualized by selected transcripts (left) and the distribution of all transcripts in the magnified area (right). Figure 3C As shown, MERFISH counts were strongly correlated with bulk RNA sequencing FPKM data (r = 0.80), indicating that the measurements were quantitative and highly accurate.

[0224] Figure 4 also shows MERFISH imaging using a 483-plex gene detection panel in FFPE mouse brain. Figure 4A The spatial distribution of selected genes in tissues is shown. Figure 4B Shown are the tissue morphology visualized by selected transcripts (left) and the distribution of all transcripts in the magnified area (right). Figure 4C As shown, MERFISH counts were strongly correlated with bulk RNA sequencing FPKM data (r = 0.88), indicating that the measurements were quantitative and highly accurate. Example 3. Comparison with other blotting and tissue cleanup protocols

[0225] This example provides a comparison of sample preparation according to certain embodiments of the present disclosure ("Protocol A") and a comparative protocol ("Protocol B") in which MERFISH (encoding or primary oligonucleotide probes) and anchor probes were added to samples prior to clearing of FFPE and fresh frozen samples ( Figure 1 ). FFPE mouse small intestine samples were treated with either protocol A or protocol B. Fresh frozen mouse small intestine samples were also treated with protocol B. All samples were then imaged via the MERSCOPE protocol (i.e., addition of MERFISH encoding probes and readout probes).

[0226] Figure 5 The average transcript counts per field of view (FOV) for both conditions are shown, indicating that samples prepared according to protocol A showed higher levels of transcript detection, indicating that more nucleic acid in the sample was anchored in the matrix and available for hybridization with the encoding probes. Example 4. MERFISH imaging in human FFPE tissue samples

[0227] This example illustrates MERFISH measurements of human FFPE tissue samples prepared according to Protocol A of the present disclosure.

[0228] Fig. 6AMERFISH imaging using a 244-plex gene panel in 15 different archived human FFPE samples is shown. For each dataset, 1000-2000 fields of view were captured, yielding tens to hundreds of millions of counts per tissue slice. Fig. 6A The top graph shows the average counts per field of view (area size 200X200μm), demonstrating that the workflow works robustly across a wide range of FFPE samples obtained from normal human tissue (top) and from human tumors (bottom). Figure 6B It is shown that the quality of MERFISH data is related to the RNA quality of the sample, as shown by the DV200 value. DV200 is the percentage of RNA fragments > 200 nucleotides in the sample. Figure 6C As shown, MERFISH counts were strongly correlated with bulk RNA sequencing FPKM data in various human tissue samples (r=0.88). Example 5. Comparison of various human FFPE samples

[0229] This example provides a comparison of MEFISH imaging of human FFPE samples according to certain embodiments of the present disclosure ("Protocol A") and a comparative protocol as described in Example 3 that can be used to match fresh frozen samples ("Protocol B").

[0230] Figure 7 It is shown that Protocol A provides high sensitivity and accuracy in different sample types compared to the comparative protocol (Protocol B). The average MERFISH counts per field of view (area size 200X 200μm) of samples prepared by Protocol A and Protocol B in different tissue types (mouse small intestine, mouse brain, human kidney, and human colon cancer) are shown, where the MERFISH counts are highly correlated. Example 6. Single cell analysis in FFPE human melanoma samples

[0231] This example demonstrates single cell analysis in FFPE human melanoma samples. As described in Example 1 above, cell segmentation was performed after antibody-based cell boundary staining. Uniform Manifold Approximation and Projection (UMAP) clustering is a dimensionality reduction method that captures variability in a limited number of random variables to facilitate visualization of data sets with tens to thousands of dimensions, which is used to define cell types in mixed populations based on gene expression profiles of individual cells, as well as for cell type identification.

[0232] The results show that the spatial distribution of selected cell types in tissues and the spatial distribution of selected gene transcripts in melanoma within the selected cell types were obtained. This shows that when prepared according to the method described in Example 1, spatial transcriptomics technology via MERFISH can be performed in FFPE samples with high detection efficiency and single molecule resolution, which ultimately provides in situ gene expression profiles in tissue samples. Data not shown. Example 7. Single cell analysis in various FFPE samples

[0233] This example demonstrates single cell analysis in various FFPE samples following the MERFISH protocol (Protocol A) according to the methods described in Example 1: A) Mouse small intestine. B) Mouse brain. C) Human liver cancer. D) Human kidney. E) Human lung. F) Human ovarian cancer. G) Human uterine cancer. H) Human lung cancer. (Top) UMAP clustering for cell type identification; (Bottom) Spatial distribution of identified cell types.

[0234] The results demonstrate that in situ single-cell transcriptomic imaging of selected gene transcripts can be performed in various tissue samples from humans and mice when FFPE samples are prepared according to the methods described in Example 1. Data not shown. Example 8. Immuno-oncology data generated using FFPE samples

[0235] A summary of the data generated using FFPE for eight (8) sample types, 16 datasets, 500 genes, approximately 4 billion transcripts, and approximately 9 million cells is shown in Table 1 below. Table 1 Sample type Total transcripts Total number of cells RIN DV200 Colon cancer 1 411,716,053 677,451 2.4 72.56 Colon cancer 2 507,576,479 817,588 3.3 87.54 Liver cancer 1 272,021,991 568,355 2.1 76.97 Liver Cancer 2 283,068,068 598,141 3.3 71.31 Melanoma 1 160,181,929 468,138 1.9 60.73 Melanoma 2 75,617,432 207,869 1.8 65.64 Ovarian cancer1 197,365,319 358,485 4.4 75.75 Ovarian Cancer2 121,798,559 254,347 4.5 74.82 Ovarian cancer3 32,054,444 71,381 4.5 74.82 Ovarian Cancer4 119,742,527 212,425 4.5 74.82 Prostate cancer1 291,996,280 721,668 3.6 87.28 Prostate Cancer2 221,331,615 993,825 3.2 79.56 Lung cancer1 144,388,044 353,762 4.3 66.97 Lung cancer 2 425,594,806 836,739 2.8 80.97 Breast cancer 490,398,542 713,121 2.7 87.37 Uterine cancer 374,580,211 843,285 3.8 78.62 total 4,129,432,299 8,696,580

[0236] Figure 10A-10C The FFPE workflow was shown to be highly sensitive, accurate, and reproducible. Fig. 10A The correlation of MERSCOPE data between two human ovarian cancer slices from the same patient is shown. The correlation coefficient is 0.99, indicating that the measurements are highly reproducible. Fig. 10B In Figure 1, human ovarian cancer sample 1 was analyzed by MERSCOPE using a 500-gene panel and adjacent slices were analyzed by bulk RNA sequencing. A correlation analysis between MERFISH counts and FPKM values ​​from bulk RNA sequencing is shown. The correlation coefficient is 0.82, indicating that the measurements are highly accurate. Fig. 10C Correlation analysis between MERSCOPE data and bulk RNA sequencing performed in 14 cancer samples is presented, and the correlation coefficients show high accuracy across multiple cancer types and replicate experiments.

[0237] Figures 11A-11F We show that the FFPE cell segmentation workflow enables the creation of realistic atlases in dense tissues. Fig.11A FFPE human hepatocellular carcinoma was immunostained using the Cell Border Staining Kit and DAPI for nuclei staining. Fig. 11B In Figure 1, cells are segmented using a deep learning-based cell segmentation algorithm. A polygonal mask for each identified cell is shown. Fig. 11C Shown is a UMAP visualization of 17 different cell types identified in human liver cancer generated from MERFISH transcript data. Fig.11D Shown in the Fig. 11B Spatial distribution of the cell types identified in the boxed areas in the tissue. Fig.11E Shown in the Fig. 11B Spatial distribution of fibroblasts in the boxed area. Fibroblast marker gene COL1A1. Fig.11F Shown is the partial distribution of endothelial cells in the boxed area from B. Endothelial marker gene PECAM1.

[0238] Fig.12 The spatial distribution of cell types identified in different FFPE tumor samples is shown. Different cancer samples including breast cancer, colon cancer, melanoma, lung cancer, liver cancer, ovarian cancer, prostate cancer and uterine cancer were analyzed by using MERSCOPE with a 500-gene detection panel and a cell border staining kit for marking cell borders. Cells were segmented and subjected to single-cell analysis. The cells identified in each sample were colored to show the spatial distribution of different cells in the sample. Scale bar: 1 mm.

[0239] Figure 13 shows that the FFPE protocol can be used to demonstrate the spatial distribution of expression of selected genes (ACTA2, CD3D, LGR5, MK167 and PECAM1) in human breast cancer. Fig.13A The spatial distribution of selected genes in tissues including ACTA2 (green), CD3D (red), LGR5 (aqua), MKI67 (magenta) and PECAM1 (blue) from the 500 genes analyzed is shown. Scale bar: 1 mm. Fig. 13B Provided Fig.13A Magnified view of the boxed area. Scale bar: 1 mm. Fig. 13C Shows Fig. 13B Magnified view of the boxed area with the cell boundary polygon mask shown in grey. Scale bar: 250 μm.

[0240] Figure 14A-14E It was shown that FFPE protocols can be used for cell type identification and mapping in human breast cancer. Fig.14AProvided are UMAP visualizations of different cell types identified in human breast cancer generated from MERFISH transcript data. Fig. 14B The spatial distribution of the 14 identified cell types in the tissue is shown. Fig. 14C Shown in Fig. 14B Spatial distribution of cell types identified in the boxed area. Fig.14D Shown in Fig. 14C The spatial distribution of two types of fibroblasts (fibroblast 1 shown in green and fibroblast 2 shown in red) in the boxed area of ​​. Both types of fibroblasts express the COL1A1 gene, while fibroblast 2 expresses the proliferation marker MKI67. Fig.14E Dot plots showing marker genes for each cell type are provided.

[0241] Figure 15 shows that FFPE protocols can be used to characterize immune cell types in the tumor microenvironment. Fig.15A A T / NK cell cluster from a breast cancer sample was selected for subcluster analysis. UMAP visualization of subcluster analysis shows seven different immune cell subtypes within human breast cancer. Fig. 15B Dot plots are provided showing marker genes for each immune cell type including myeloid cells, CD4+ T cells, CD8+ T cells, CD4+ regulatory T cells (Tregs), and NK lineage cells. Fig. 15C The spatial distribution of Tregs is provided. Fig.15D The spatial distribution of CD4+ T cells is provided. Fig.15E The spatial distribution of selected genes in the amplified region in human breast cancer is provided, wherein CD4 (green), CD8A (blue), FOXP3 (red), NCR1 (yellow) and CTLA4 (white) are shown. Note that FOXP3 positive Tregs express T cell exhaustion markers (CTLA4 is marked with a red arrow; NK cells are marked with a yellow arrow).

Claims

1. A method for anchoring a target nucleic acid in a matrix and clearing non-target cell components, the method comprising: a. contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid and the second anchoring agent comprises an oligonucleotide that hybridizes to the target nucleic acid; b. embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; and, c. clearing the non-target cellular components from the polymer matrix, wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix-anchored target nucleic acid sample. The method of claim 1 , wherein the first anchoring agent is an alkylating agent.

3. The method of claim 2, wherein the alkylating agent is selected from the group consisting of altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, nitrogen mustard, melphalan, oxaliplatin, temozolomide, thiotepa and trabectedin.

4. The method of claim 1, wherein the second anchor comprises alternating dT and locked dT portions that hybridize to the target nucleic acid.

5. The method of claim 1, wherein the second anchor comprises a poly dT moiety that hybridizes to the target nucleic acid.

6. The method of claim 1, wherein the first anchoring agent and the second anchoring agent each comprise an acrydite moiety covalently bound to the polymer matrix.

7. The method of claim 1, wherein the first anchoring agent is an alkylating agent derivatized with an acrydite moiety.

8. The method of claim 1, wherein the second anchoring agent comprises a poly dT moiety that hybridizes to the target nucleic acid and an acrydite moiety that is covalently bound to the polymer matrix.

9. The method of claim 1, wherein the target nucleic acid is RNA.

10. The method of claim 1, wherein the target nucleic acid is DNA.

11. The method of claim 1, further comprising contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes that hybridize to the target nucleic acid.

12. The method of claim 11, wherein the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robust fluorescence in situ hybridization (MERFISH) probe.

13. The method of claim 11, wherein the one or more primary oligonucleotide probes comprise a first portion comprising a target sequence and a second portion comprising one or more reading sequences.

14. The method of claim 13, further comprising determining a read sequence based on contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising recognition sequences that hybridize to the read sequence of the primary nucleic acid probes.

15. The method of claim 1, further comprising imaging using multiplexed fluorescent in situ hybridization, comprising contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes that hybridize to the target nucleic acid, and comprising one or more sequential steps of adding multiple secondary nucleic acid probes comprising a label portion.

16. The method of claim 1, further comprising imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, comprising contacting the anchored target nucleic acid sample with one or more MERFISH probes that hybridize to the target nucleic acid.

17. The method of claim 13, further comprising imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally distinct fluorescent label, are used to read out multiple readout sequences simultaneously.

18. A method for anchoring a target RNA in a matrix and clearing non-target cell components, the method comprising: a. contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent comprises an alkylating agent that forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises a poly-T sequence that is complementary to and hybridizes to the target RNA, and wherein the first anchoring agent and the second anchoring agent each comprise an acrydite moiety that is covalently bound to the matrix; b. embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; and, c. clearing the non-target cellular components from the polymer matrix, wherein the target RNA remains anchored in the polymer matrix to form a matrix-anchored target RNA sample.

19. The method of claim 18, wherein the alkylating agent is selected from the group consisting of altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, nitrogen mustard, melphalan, oxaliplatin, temozolomide, thiotepa, and trabectedin.

20. The method of claim 18, wherein the second anchor comprises alternating dT and lock dT portions that hybridize to the target RNA.

21. The method of claim 18, further comprising contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes that hybridize to the target nucleic acid.

22. The method of claim 21, wherein the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robust fluorescence in situ hybridization (MERFISH) probe.

23. The method of claim 21, wherein the one or more primary oligonucleotide probes comprise a first portion comprising a target sequence and a second portion comprising one or more reading sequences.

24. The method of claim 23, further comprising determining a read sequence based on contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising recognition sequences that hybridize to the read sequence of the primary nucleic acid probes.

25. The method of claim 18, further comprising imaging using multiplexed fluorescent in situ hybridization, comprising contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes that hybridize to the target nucleic acid, and comprising one or more sequential steps of adding a plurality of secondary nucleic acid probes comprising a label portion.

26. The method of claim 18, further comprising imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, comprising contacting the anchored target nucleic acid sample with one or more MERFISH probes that hybridize to the target nucleic acid.

27. The method of claim 23, further comprising imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally distinct fluorescent label, are used to read out multiple readout sequences simultaneously.

28. A method for imaging a target nucleic acid within a matrix and clearing non-target cellular components, the method comprising: a. contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent forms a covalent bond with the target nucleic acid and the second anchoring agent comprises an oligonucleotide that hybridizes to the target nucleic acid; b. embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; c. clearing the non-target cellular components from the polymer matrix, wherein the target nucleic acid remains anchored in the polymer matrix to form a matrix-anchored target nucleic acid sample; as well as, d. contacting the anchored target nucleic acid sample with one or more primary oligonucleotide probes that hybridize to the target nucleic acid and a plurality of secondary nucleic acid probes that contain fluorescent labels and recognition sequences that hybridize to the sequences of the primary nucleic acid probes, and imaging the target nucleic acid.

29. The method of claim 28, wherein the first anchoring agent is an alkylating agent.

30. The method of claim 29, wherein the alkylating agent is selected from the group consisting of altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, temozolomide, thiotepa, and trabectedin.

31. The method of claim 28, wherein the second anchor comprises alternating dT and locked dT portions that hybridize to the target nucleic acid.

32. The method of claim 28, wherein the second anchor comprises a poly dT moiety that hybridizes to the target nucleic acid.

33. The method of claim 28, wherein the first anchoring agent and the second anchoring agent each comprise an acrydite moiety covalently bound to the polymer matrix.

34. The method of claim 28, wherein the first anchoring agent is an alkylating agent derivatized with an acrydite moiety.

35. The method of claim 28, wherein the second anchor comprises a poly dT moiety that hybridizes to the target nucleic acid and an acrydite moiety that is covalently bound to the polymer matrix.

36. The method of claim 28, wherein the target nucleic acid is RNA.

37. The method of claim 28, wherein the target nucleic acid is DNA.

38. The method of claim 28, wherein the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robust fluorescence in situ hybridization (MERFISH) probe.

39. The method of claim 28, wherein the one or more primary oligonucleotide probes comprise a first portion comprising a target sequence and a second portion comprising one or more reading sequences.

40. The method of claim 39, further comprising determining a read sequence based on contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising recognition sequences that hybridize to the read sequence of the primary nucleic acid probes.

41. The method of claim 28, wherein the secondary nucleic acid probe is added in one or more sequential steps and imaging is performed between each sequential round of adding the secondary nucleic acid probe.

42. The method of claim 28, further comprising imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, comprising contacting the anchored target nucleic acid sample with one or more MERFISH probes that hybridize to the target nucleic acid.

43. The method of claim 40, further comprising imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally distinct fluorescent label, are used to read out multiple readout sequences simultaneously.

44. A method for imaging target RNA within a matrix and clearing non-target cellular components, the method comprising: a. contacting a formalin-fixed paraffin-embedded (FFPE) tissue sample with at least two anchoring agents, wherein the first anchoring agent comprises an alkylating agent that forms a covalent bond with the target nucleic acid, and the second anchoring agent comprises a poly-T sequence that is complementary to and hybridizes to the target RNA, and wherein the first anchoring agent and the second anchoring agent each comprise an acrydite moiety that is covalently bound to the matrix; b. embedding the sample in a polymer matrix, wherein the first anchoring agent and the second anchoring agent each form a covalent bond with the polymer matrix; c. clearing the non-target cellular components from the polymer matrix, wherein the target RNA remains anchored in the polymer matrix to form a matrix-anchored target RNA sample; and, d. contacting the anchored target RNA sample with one or more primary oligonucleotide probes that hybridize with the target RNA and a plurality of secondary nucleic acid probes that contain fluorescent labels and recognition sequences that hybridize with the sequences of the primary nucleic acid probes, and imaging the target nucleic acid.

45. The method of claim 44, wherein the alkylating agent is selected from the group consisting of altretamine, bendamustine, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, oxaliplatin, temozolomide, thiotepa, and trabectedin.

46. ​​The method of claim 44, wherein the second anchor comprises alternating dT and locked dT portions that hybridize to the target nucleic acid.

47. The method of claim 44, wherein the primary oligonucleotide probe is a single molecule (sm) FISH probe or a multiplexed error robust fluorescence in situ hybridization (MERFISH) probe.

48. The method of claim 44, wherein the one or more primary oligonucleotide probes comprise a first portion comprising a target sequence and a second portion comprising one or more reading sequences.

49. The method of claim 48, further comprising determining a read sequence based on contacting the one or more primary oligonucleotide probes with a plurality of secondary nucleic acid probes comprising recognition sequences that hybridize to the read sequence of the primary nucleic acid probes.

50. The method of claim 44, wherein the secondary nucleic acid probe is added in one or more sequential steps and imaging is performed between each sequential round of adding the secondary nucleic acid probe.

51. The method of claim 44, further comprising imaging using multiplexed error robust fluorescent in situ hybridization (MERFISH) probes, comprising contacting the anchored target nucleic acid sample with one or more MERFISH probes that hybridize to the target nucleic acid.

52. The method of claim 49, further comprising imaging using multiple rounds of fluorescent in situ hybridization, wherein in each round, one or more different secondary nucleic acid probes, each conjugated to a spectrally distinct fluorescent label, are used to read out multiple readout sequences simultaneously.

53. The method of any one of claims 1-52, wherein the tissue sample is deparaffinized and rehydrated prior to step (a).

54. The method of any one of claims 1-53, wherein the polymer matrix comprises polyacrylamide.

55. The method of any one of claims 1-54, wherein step (b) of embedding the sample comprises polymerizing the polymer matrix within the tissue sample, wherein the first anchoring agent and the second anchoring agent are each copolymerized with the polymer matrix.

56. The method of any one of claims 1-55, wherein the non-target cell components comprise proteins, lipids, DNA, RNA, or extracellular matrix.

57. The method of any one of claims 1-56, wherein clearing the non-target cellular components comprises removing or degrading proteins from the sample.

58. The method of any one of claims 1-57, wherein clearing the non-target cellular components comprises removing or degrading lipids from the sample.

59. The method of any one of claims 1-58, wherein clearing the non-target cellular components comprises removing or degrading non-target DNA from the sample.

60. The method of any one of claims 1-59, wherein clearing the non-target cellular components comprises removing or degrading extracellular matrix from the sample.

61. The method of any one of claims 1-60, wherein clearing the non-target cellular components comprises exposing the sample to an enzyme capable of degrading proteins.

62. The method of any one of claims 1-59, wherein clearing the non-target cellular components comprises exposing the sample to an enzyme capable of degrading DNA.

63. The method of any one of claims 1-62, wherein clearing the non-target cellular components comprises exposing the sample to an enzyme capable of degrading RNA.

64. The method of any one of claims 1-63, wherein clearing the non-target cellular components comprises exposing the sample to an enzyme capable of degrading a sugar or sugar-modified biomolecule.

65. The method of any one of claims 1-64, wherein clearing the non-target cellular components comprises exposing the sample to a detergent.

66. The method of any one of claims 1-65, wherein clearing the non-target cell components comprises exposing the gel to a protease.

67. The method of claim 66, wherein the protease comprises proteinase K.

68. The method of any one of claims 1-67, wherein clearing the non-target cellular components comprises exposing the polymer matrix to guanidine hydrochloride.

69. The method of any one of claims 1-68, wherein clearing the non-target cell components comprises exposing the gel to Triton X-100 (polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenyl ether).

70. The method of any one of claims 1-69, wherein clearing the non-target cellular components comprises exposing the polymer matrix to sodium dodecyl sulfate.

71. The method of any one of claims 1-70, wherein clearing the non-target cellular components comprises exposing the polymer matrix to ethylenediaminetetraacetic acid.

72. The method of any one of claims 28-71, further comprising amplification of the primary oligonucleotide probe.

73. The method of any one of claims 28-72, wherein the imaging comprises using epifluorescence microscopy, total internal reflection microscopy, highly inclined thin illumination (HILO) microscopy, light sheet microscopy, scanning confocal microscopy, scanning line confocal microscopy, spinning disk confocal microscopy, or other comparable conventional microscopy techniques.

74. The method of claim 73 comprising imaging using multiplexed fluorescence in situ hybridization.

75. The method of any one of claims 28-74, wherein the primary oligonucleotide probes are present in probe pools, wherein each pool hybridizes to a different nucleic acid target, and each probe pool encodes an N-bit binary code assigned to each different nucleic acid target via a read sequence.

76. The method of claim 75, wherein the N-bit binary code has a Hamming weight of at least 2.

77. The method of any one of claims 1-76, wherein the integrity of the nucleic acid is determined prior to step a).

Citation Information

Cited By

  • Biological tissue treatment method for fluorescence in situ hybridization and application

    CN122104871A